AU763615B2 - Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption - Google Patents
Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption Download PDFInfo
- Publication number
- AU763615B2 AU763615B2 AU50599/99A AU5059999A AU763615B2 AU 763615 B2 AU763615 B2 AU 763615B2 AU 50599/99 A AU50599/99 A AU 50599/99A AU 5059999 A AU5059999 A AU 5059999A AU 763615 B2 AU763615 B2 AU 763615B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- phenyl
- bone resorption
- treatment
- abnormal bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title claims description 94
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title claims description 94
- 229940044551 receptor antagonist Drugs 0.000 title claims description 92
- 239000002464 receptor antagonist Substances 0.000 title claims description 92
- 208000006386 Bone Resorption Diseases 0.000 title claims description 85
- 230000024279 bone resorption Effects 0.000 title claims description 84
- 230000002159 abnormal effect Effects 0.000 title claims description 74
- 150000001875 compounds Chemical class 0.000 claims description 78
- 238000011282 treatment Methods 0.000 claims description 67
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 62
- 229940122361 Bisphosphonate Drugs 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 150000004663 bisphosphonates Chemical class 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 54
- -1 bromo, iodo Chemical group 0.000 claims description 50
- 230000002265 prevention Effects 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 39
- 229940011871 estrogen Drugs 0.000 claims description 35
- 239000013543 active substance Substances 0.000 claims description 33
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 32
- 208000001132 Osteoporosis Diseases 0.000 claims description 30
- 239000002834 estrogen receptor modulator Substances 0.000 claims description 29
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 239000000813 peptide hormone Substances 0.000 claims description 28
- 239000000849 selective androgen receptor modulator Substances 0.000 claims description 28
- 206010065687 Bone loss Diseases 0.000 claims description 24
- 210000000988 bone and bone Anatomy 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 23
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 229940062527 alendronate Drugs 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 239000011737 fluorine Substances 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000000262 estrogen Substances 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 125000006413 ring segment Chemical group 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 6
- 230000008416 bone turnover Effects 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 claims description 5
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 5
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 5
- 208000027868 Paget disease Diseases 0.000 claims description 5
- 206010052306 Periprosthetic osteolysis Diseases 0.000 claims description 5
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 5
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical group O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 claims description 5
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 5
- 229960002286 clodronic acid Drugs 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 229940009626 etidronate Drugs 0.000 claims description 5
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 claims description 5
- 229940015872 ibandronate Drugs 0.000 claims description 5
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 claims description 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 208000027202 mammary Paget disease Diseases 0.000 claims description 5
- 208000028169 periodontal disease Diseases 0.000 claims description 5
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 5
- 229940089617 risedronate Drugs 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 229960003604 testosterone Drugs 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 125000001425 triazolyl group Chemical group 0.000 claims description 5
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 5
- 229960004276 zoledronic acid Drugs 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 4
- 201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 4
- 229950006971 incadronic acid Drugs 0.000 claims description 4
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 4
- 229940046231 pamidronate Drugs 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- 102000055006 Calcitonin Human genes 0.000 claims description 3
- 108060001064 Calcitonin Proteins 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 229960004015 calcitonin Drugs 0.000 claims description 3
- 125000002346 iodo group Chemical group I* 0.000 claims description 3
- 229960003327 ormeloxifene Drugs 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 3
- MFKMXUFMHOCZHP-RQZHXJHFSA-N 1-[2-[4-[(z)-1-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]ethyl]pyrrolidine Chemical compound C1=CC(OC)=CC=C1C(\C=1C=CC(OCCN2CCCC2)=CC=1)=C([N+]([O-])=O)/C1=CC=CC=C1 MFKMXUFMHOCZHP-RQZHXJHFSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 claims description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 2
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims description 2
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims description 2
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 claims description 2
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 claims description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 2
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 claims description 2
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 claims description 2
- 229950009148 androstenediol Drugs 0.000 claims description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical group C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 claims description 2
- 229960000766 danazol Drugs 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 2
- 229950004203 droloxifene Drugs 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 229950002248 idoxifene Drugs 0.000 claims description 2
- 229950002366 nafoxidine Drugs 0.000 claims description 2
- 229950004982 nitromifene Drugs 0.000 claims description 2
- 229940053934 norethindrone Drugs 0.000 claims description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
- 229960000464 oxandrolone Drugs 0.000 claims description 2
- 229960005244 oxymetholone Drugs 0.000 claims description 2
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 claims description 2
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 claims description 2
- 229960000912 stanozolol Drugs 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
- 229960005026 toremifene Drugs 0.000 claims description 2
- 229950000212 trioxifene Drugs 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 1
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 description 46
- 239000003826 tablet Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 18
- 238000003556 assay Methods 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 125000001624 naphthyl group Chemical group 0.000 description 12
- 238000010079 rubber tapping Methods 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 9
- 241000699694 Gerbillinae Species 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229920002261 Corn starch Polymers 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000008120 corn starch Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 229960004343 alendronic acid Drugs 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 5
- 102100024304 Protachykinin-1 Human genes 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 125000005493 quinolyl group Chemical group 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101800003906 Substance P Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 238000009806 oophorectomy Methods 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000282339 Mustela Species 0.000 description 3
- 241000036848 Porzana carolina Species 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229910052701 rubidium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000012431 wafers Nutrition 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010041652 GR 73632 Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000282341 Mustela putorius furo Species 0.000 description 2
- 229910003827 NRaRb Inorganic materials 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229910003667 SRa Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000003141 Tachykinin Human genes 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000030991 negative regulation of bone resorption Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 2
- 230000001599 osteoclastic effect Effects 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 108060008037 tachykinin Proteins 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RENWFOYENNEQJW-HLAWJBBLSA-N (2s)-2-[3,5-bis(trifluoromethyl)phenyl]-2-[(2r,3s)-3-(4-fluorophenyl)-4-(1h-1,2,4-triazol-5-ylmethyl)morpholin-2-yl]oxyethanol Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](CO)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC=1N=CNN=1 RENWFOYENNEQJW-HLAWJBBLSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- UGIPKCIBIXXIEF-HNAYVOBHSA-N (2s,3s)-3-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-1-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1C[C@H]1[C@@H](C=2C=CC=CC=2)N(N)CCC1 UGIPKCIBIXXIEF-HNAYVOBHSA-N 0.000 description 1
- DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 description 1
- XILNRORTJVDYRH-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC)N2C(=NN=N2)C(F)(F)F)=CC=CC=C1 XILNRORTJVDYRH-HKUYNNGSSA-N 0.000 description 1
- ACSJGOJPLODBLW-DZFGPLHGSA-N (3r,5r,10s)-3-(2-methoxyphenyl)-10-phenyl-1-oxa-9-azaspiro[4.5]decane Chemical compound COC1=CC=CC=C1[C@H]1C[C@]2([C@@H](NCCC2)C=2C=CC=CC=2)OC1 ACSJGOJPLODBLW-DZFGPLHGSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KYHMFVRVHASKGM-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindol-4-ol Chemical compound OC1CCCC2CNCC12 KYHMFVRVHASKGM-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- XRCFMDPVHKVRDJ-BGJMDTOESA-N 3,17-dioxoandrost-4-en-19-al Chemical compound O=C1CC[C@]2(C=O)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 XRCFMDPVHKVRDJ-BGJMDTOESA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000028906 Abnormal bone structure Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- UMRURYMAPMZKQO-NDKKBYRMSA-N Clometherone Chemical compound C1([C@@H](Cl)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(C)=O)[C@@]2(C)CC1 UMRURYMAPMZKQO-NDKKBYRMSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 125000003705 anilinocarbonyl group Chemical group O=C([*])N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229950006309 delmadinone Drugs 0.000 description 1
- ZSAMZEYLGUEVJW-TTYLFXKOSA-N delmadinone Chemical compound C1=C(Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZSAMZEYLGUEVJW-TTYLFXKOSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- ZMITXKRGXGRMKS-LUJOEAJASA-N epiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 ZMITXKRGXGRMKS-LUJOEAJASA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 230000001089 mineralizing effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229960000492 norethandrolone Drugs 0.000 description 1
- ZDHCJEIGTNNEMY-XGXHKTLJSA-N norethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 ZDHCJEIGTNNEMY-XGXHKTLJSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000005646 oximino group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical group [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003484 testosterone enanthate Drugs 0.000 description 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
WO 00/07598 PCT/GB99/02509 -1- USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION This invention relates to the treatment or prevention of abnormal bone resorption by the administration of a NK-1 receptor antagonist, optionally in combination with one or more active agents from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones.
The term "abnormal bone resorption", as used herein means a degree of bone resorption that exceeds the degree of bone formation, either locally, or in the skeleton as a whole. "Abnormal bone resorption" can also be associated with the formation of bone having an abnormal structure.
A variety of disorders in humans and other mammals involve or are associated with abnormal bone resorption. Such disorders include, but are not limited to, osteoporosis, Paget's disease, peridontal disease, periprosthetic bone loss or osteolysis, and hypercalcemia of malignancy.
The most common of these disorders is osteoporosis, which in its most frequent manifestation occurs in postmenopausal women. Osteoporosis is a systemic skeletal disease characterized by a low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporotic patients usually experience bone resorption in excess of bone formation, causing chronic bone loss. Because osteoporosis, as well as other disorders associated with ongoing bone loss, are chronic conditions, it is believed that appropriate therapy will generally require chronic treatment.
Multinucleated cells called osteoclasts are responsible for a process known as bone resorption. In osteoporosis, the bone resorption rate exceeds the bone formation rate, causing net bone loss. It is well known that bisphosphonates are selective inhibitors of osteoclastic bone resorption, making these compounds important therapeutic agents in the treatment or prevention of a variety of generalized or localized bone WO 00/07598 PCT/GB99/02509 -2disorders caused by or associated with abnormal bone resorption. See H.
Fleisch, Bisphosphonates In Bone Disease, From The Laboratory To The Patient, 2nd Edition, Parthenon Publishing (1995), which is incorporated by reference herein in its entirety.
At present, a great amount of preclinical and clinical data exists for the potent bisphosphonate compound alendronate. Evidence suggests that other amino-bisphosphonates such as risedronate, ibandronate and zoledronate, have many properties in common with alendronate, including both high bone specificity and potency as inhibitors of osteoclastic bone resorption. An older non-amino-bisphosphonate compound, etidronate, also inhibits bone resorption. However, unlike the more potent bisphosphonates, etidronate impairs mineralization at doses used clinically, and may give rise to osteomalacia, a condition resulting in an undesirable decrease in bone mineralization and bone strength. See Boyce, B. Fogelman, Ralston, S. et al. (1984) Lancet 1(8381), pp. 821- 824 (1984), and Gibbs, C. Aaron, J. Peacock, M. (1986) Br. Med. J.
292, pp. 1227-1229 (1986), both of which are incorporated by reference herein in their entirety.
Peak bone mass in women is achieved at around 30-35 years of age.
Bone mass is then relatively stable until the perimenopausal period (usually the late fifth decade of life). The rate of bone loss accelerates markedly during the early post menopausal period to a rate of 3-4% annually, especially at sites with a high component of trabecular bone.
After 8-10 years of menopausal life, the bone loss rate slowly stabilizes at about 1% annually.
The average woman has a greater than 40% chance of developing at least one osteoporotic fracture during her lifetime. Osteoporotic fractures, especially of the hip, occur in 16% of all women reaching 80 years of age, and are associated with a marked reduction in the quality of life and high cost of treatment. The total costs and morbidity associated with all WO 00/07598 PCT/GB99/02509 -3osteoporotic fractures are certain to substantially exceed those of hip fracture alone, although precise estimates are not available.
Apart from bisphosphonates such as alendronate, other generally recognised therapies for prevention of osteoporosis are estrogen replacement therapy, raloxifene, a selective estrogen receptor modulator, and calcitonin. Along with preventing of bone loss associated with reduced endogenous estrogen production, administration of estrogen can help reduce post menopausal symptoms such as vasomotor instability, vaginal atrophy, and increased incidence of cardiovascular problems, possibly associated with a deterioriation in the lipid profile. However, at the doses of estrogen commonly employed for bone loss prevention, some women continue to lose bone during treatment. Furthermore, estrogen treatment is also associated with some serious risks, including endometrial carcinoma, symptomatic gall bladder disease, deep vein thrombosis and an increased incidence of breast cancer. Although some of these risks can be lowered by addition of progestins to the therapeutic regimen, a large proportion of women will not accept long-term estrogen treatment mainly because of breakthrough bleeding and safety concerns.
It would be desirable to have an agent other than a bisphosphonate, that prevents osteoporosis without the risks and side effects associated with estrogen.
Neurokinin 1 (NK-1; substance P) receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinins, and in particular substance P. To date, the role of substance P in abnormal bone resorption, and the use of NK-1 receptor antagonists to treat or prevent abnormal bone resorption, has not been elucidated.
We have now found that NK-1 receptor antagonists are effective in the treatment of abnormal bone resorption, as evidenced by their effect on bone density in vivo in an animal model of inflammatory joint disease.
4 Furthermore, a combination of a NK-1 receptor antagonist with a bisphosphonate may provide enhanced inhibition of bone resorption over that provided by the bisphosphonate alone. They may also allow for a reduced dosage or frequency of dosing with the bisphosphonate which would be particularly advantageous when side-effects are a liability with high dosage or chronic administration regimens.
There is disclosed herein the use of a NK-1 receptor antagonist for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
There is further disclosed herein a method for the treatment or prevention of abnormal bone resorption, which method comprises administration to a patient in need of such treatment an effective amount of a NK-1 receptor antagonist.
There is also disclosed herein a pharmaceutical composition for the treatment or prevention of abnormal bone resorption comprising a NK-1 receptor antagonist, together with at least one pharmaceutically acceptable carrier or excipient.
In addition to monotherapy, the NK-1 receptor antagonist may be administered in combination with one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones.
There is further disclosed herein the use of a NK-1 receptor antagonist and one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, for Sthe manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
There is yet further disclosed herein a method for the treatment or prevention of abnormal bone resorption, which method comprises administration to a patient in need of such treatment a therapeutically effective amount of a NK-1 receptor antagonist and one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators and peptide hormones, such that together they give effective relief.
There is also disclosed herein a pharmaceutical composition comprising a NK-1 S 30 receptor antagonist and one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, together with at least one pharmaceutically acceptable carrier or excipient.
It will be appreciated that the NK-1 receptor antagonist and the additional active agent(s) may be present as a combined preparation for simultaneous, separate or [R:\LIBXX]04068.doc:aak sequential use for the treatment or prevention of abnormal bone resorption. Such combined preparations may be, for example, in the form of a twin pack.
There is further disclosed herein a product comprising a NK-1 receptor antagonist and one or more active agents selected from, but not limited to, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of abnormal bone resorption.
The methods and compositions of the present invention are useful for both treating and preventing abnormal bone resorption and conditions associated therewith.
According to the disclosure, when used in combination therapy, the NK-1 receptor antagonist is administered in combination with one or more active agents selected from the group consisting of bisphosphonates, estrogen receptor modulators, and peptide hormones.
When used in combination therapy, the NK-1 receptor antagonist is preferably administered in combination with a bisphosphonate.
Conditions associated with abnormal bone resorption include both generalized and localized bone loss. The term "generalized bone loss" means bone loss at multiple skeletal sites or throughout the skeletal system. The term "localized bone loss" means bone loss at one or more specific, defined skeletal sites.
According to a first embodiment the present invention provides use of a NK-1 Sreceptor antagonist of formula R 3 X R 4
R
2
RS
R
(I)
or a pharmaceutically acceptable salt thereof, wherein: R' is selected from the group consisting of: C i6alkyl, substituted with one or more of the substituents selected from: S* a) heterocycle, wherein the heterocycle is selected from the group consisting of: S* benzimidazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, [R:\LIBXX]04068.doc:aak pyrazinyl, pyrazolyl, pyridyl, pyrrolyl, tetrazolyl, thiadiazolyl, triazolyl, and piperidinyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from:
C
1 6 alkyl, unsubstituted or substituted with halo, -CF 3
-OCH
3 or phenyl, (11) C 1 6 alkoxy, (iii) oxo, (iv) thioxo, cyano, (vi) -SCH 3 (vii) phenyl, (viii) hydroxy, (ix) trifluoromethyl,
-(CH
2 )m-NR 9
R
10 wherein m is 0, 1 or 2, and R 9 and R1 0 are independently selected from: hydrogen, (11) C I 6 alkyl, ~(111) hydroxy C I 6 alkyl, and phenyl, (xi) -NR 9
COR'
0 wherein R 9 and R 10 are as defined above, and (xii) -CONR 9
R'
0 wherein R 9 and R 10 are as defined above, R 2and R 3 are independently selected from the group consisting of: 0 hydrogen; C I 6 alkyl;
C
2 6 alkenyl, and phenyl; X is R 4i [R:\LIBXX]04068.doc:aak
R
5 is phenyl, unsubstituted or substituted with halo; R R 7 and R 8 are independently selected from the group consisting of: hydrogen, Ci-6alkyl, halo, and
-CF
3 Y is and Z is hydrogen or CI.
4 alkyl; or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
According to a second embodiment the present invention provides use of a NK-1 receptor antagonist of formula (II):
A
1
Y
N 3
I
.R6/ A3 15i (II) wherein: A' is fluorine or CF 3
A
2 is fluorine or CF 3
A
3 is fluorine or hydrogen; 20 R 6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =S or a Ci- 4 alkyl group, and optionally substituted by a group of the formula ZNR 7
R
8 where Z is Ci-6alkylene or C3-6cycloalkylene; S* R 7 is hydrogen, C14alkyl, C3-7cycloalkyl or C3-7cycloalkylC-4alkyl, or C24alkyl 25 substituted by Cl-4alkoxy or hydroxyl; [R:\LIBXX]04068.doc:aak
R
8 is hydrogen, Cl4alkyl, C3- 7 cycloalkyl or C3.7cycloalkyiC 1 4 alkyi, or C24alkyl substituted by one or two substituents selected from Cl4alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and
S;
or R 7 R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by a hydroxy group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(0) or S(0) 2 or a second nitrogen atom which will be part of a NH or NRc moiety where R is Cl4alkyl optionally substituted by hydroxy or CI.
4 alkoxy; or R 7
R
8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms; or Z, R 7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo; and Y is a Ci- 4 alkyl group optionally substituted by a hydroxyl group; with the proviso that if Y is Ci.
4 alkyl, R 6 is substituted at least by a group of formula ZNR 7
R
8 as defined above; or a pharmaceutically acceptable salt thereof; for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
According to a third embodiment the present invention provides use of a NK-1 Sreceptor antagonist of formula (III):
R.
9
R
2R6 R N
R
2 and R 3 are independently selected from the group consisting of: hydrogen, CC0. Cl~ 6 alkyl,
C
2 6 alkenyl, and (2)C -alyl (3
R
13 akeyl and [R:\LIBXX]04068.doc:aak phenyl; R 6, R 7 and R 8 are independently selected from the group consisting ofhydrogen, C 1 6 alkyl, fluoro, chloro, bromo, iodo, and
-CF
3 R 1 2 and R" 3 are independently selected from the group consisting of: fluoro, chloro, bromo, and iodo; A is unsubstituted i.
6 alkyI; B is selected from the group consisting of:
H
N-N
N S x N-N
H
N-N
H
X
H
N-N
H
N-N
N 0 x
H
N-N
N-N"'
X/N,S/ x 0 0 0
N-N"
No
H
N
N'S
x
N
1 x
H
N 0
N'
x x
NS
H~
H
N S P isO0 or 1; [R:\LIBXX]04068.doc:aak 6d X is selected from: -PO(OH)cY e M+ is a pharmaceutically acceptable monovalent counterion, -PO(0-) 2 9 2M+, -PO(0-) 2
D
2 wherein D 2 is a pharmaceutically acceptable divalent countenion,
-CH(R
4 )-PO(OH)EY wherein R 4 is hydrogen or CI.
3 alkyl,
-CH(R
4 2 2M+,
-CH(R
4 2 o.
-CO-CH
2
CH
2 -C0 2
*M,
-CH(CH
3 )-O-CO-R 5 wherein R 5 isselected from the group consisting of:
+M
(ii)
O
(iii) C02M CO V (iv) C0jM Y C0 2
NH
3 KC02-M+ O. -0 C2M C0 2
_M
0 M (vii) ,and Y is Z is hydrogen or C 1 6 alkyl; 20 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
According to a fourth embodiment the present invention provides use of a NK-1 .receptor antagonist as defined in the -first, second or third embodiments in combination [1:\DAYLIB\LLBH]02553.doc:sxc 6e with one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
According to a fifth embodiment the present invention provides use of a NK-1 receptor antagonist as defined in the first, second or third embodiments and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
According to a sixth embodiment the present invention provides a pharmaceutical 1o composition comprising a NK-1 receptor antagonist as defined in the first, second or third embodiments and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, together with at least one pharmaceutically acceptable carrier or excipient.
According to a seventh embodiment the present invention provides a product comprising a NK-1 receptor antagonist as defined in the first, second or third embodiments and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of abnormal bone resorption.
According to an eighth embodiment the present invention provides a method for the treatment or prevention of abnormal bone resorption said method comprising administration to a patient in need of such treatment a therapeutically effective amount of NK- 1 receptor antagonist of formula as defined in the first embodiment.
"-According to a ninth embodiment the present invention provides a method for the 25 treatment or prevention of abnormal bone resorption said method comprising :"administration to a patient in need of such treatment a therapeutically effective amount of a compound of formula (II) as defined in the second embodiment.
According to a tenth embodiment the present invention provides a method for the treatment or prevention of abnormal bone resorption said method comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of formula (III), as defined in the third embodiment.
According to an eleventh embodiment the present invention provides a method for the treatment or prevention of abnormal bone resorption said method comprising gadministration to a patient in need of such treatment a therapeutically effective amount of a:.et a NK-1 receptor antagonist, as defined in the first, second or third embodiments in .0i [I:\DAYLIB\LIBH]02553.doc:sxc 6f combination with one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones.
According to a twelfth embodiment the present invention provides a method for the treatment or prevention of abnormal bone resorption said method comprising administration to a patient in need of such treatment a therapeutically effective amount of a NK-1 receptor antagonist, as defined in the first, second or third embodiments and one or more active agents selected from the group consisting ofbisphosphonates, estrogen and androgen receptor modulators, and peptide hormones.
According to a thirteenth embodiment the present invention provides use of a NK-1 1o receptor antagonist of formula as defined in the first embodiment, when used for the treatment or prevention of abnormal bone resorption.
According to a fourteenth embodiment the present invention provides a NK-1 receptor antagonist of formula (II) as defined in the second embodiment, when used for the treatment or prevention of abnormal bone resorption.
According to a fifteenth embodiment the present invention provides use of a NK-1 receptor antagonist of formula (III) as defined in the third embodiment when used for the treatment or prevention of abnormal bone resorption.
According to a sixteenth embodiment the present invention provides use of a NK-1 receptor antagonist, as defined in the first, second or third embodiments in combination with one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, when used for the treatment or prevention of abnormal bone resorption.
According to a seventeenth embodiment the present invention provides a NK-1 •.receptor antagonist, as defined in the first, second or third embodiments and one or more 25 active agents selected from the group consisting of bisphosphonates, estrogen and •o0• androgen receptor modulators, and peptide hormones, when used for the treatment or prevention of abnormal bone resorption.
Generalized bone loss is usually associated with osteoporosis. Osteoporosis is most common in post-menopausal women, wherein estrogen production has diminished.
However, osteoporosis can also be glucocorticoid-induced and has been observed in males due to age and reduced androgen production. Osteoporosis can be induced by *...disease, e.g. rheumatoid arthritis; by secondary causes, glucocorticoid therapy; or by no identifiable cause, i.e. idiopathic osteoporosis, possibly of inherited origin. In the present invention, preferred methods include the treatment or prevention of abnormal 35 bone resorption in osteoporotic humans.
[I:\DAYL1B\L1BHj02553.doc:sxc 6g Localized bone loss has been associated with periodontal disease and periprosthetic osteolysis where bone resorption has occurred in proximity to a dental or orthopaedic prosthetic implant.
Generalized or localized bone loss can occur from disuse, often a problem for those confined to a bed or a wheelchair, those who have an immobilized limb set in a cast or held in traction, or those who suffer permanently disabling strokes.
The methods and compositions of the present disclosure are useful for treating and/or preventing the following conditions or disease states: osteoporosis, including postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, male osteoporosis, disease-induced osteoporosis, and idiopathic osteoporosis; Paget's disease; abnormally increased bone turnover; hypercalcemia of malignancy; osteogensis imperfecta; periodontal disease; periprosthetic osteolysis; and abnormal bone resorption associated with immunosuppressive therapy.
The term "pharmaceutically effective amount", as used herein, means that amount of the NK-1 receptor antagonist and (where present) [1:\DAYLIB\LIBHj02553.doc:sxc WO 00/07598 PCT/GB99/02509 -7the additional active agent(s), that will elicit the desired therapeutic effect or response when administered in accordance with the desired treatment regimen. A preferred pharmaceutically effective amount of the NK-1 receptor antagonist and (where present) the additional active agent(s) is a bone resorption inhibiting amount.
The term "bone resorption inhibiting", as used herein, means preventing bone resorption by the direct or indirect alteration of osteoclast formation or activity. Inhibition of bone resorption refers to prevention of bone loss, especially the inhibition of removal of existing bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity.
It will be appreciated that the NK-1 receptor antagonist and any additional active agent(s) should be continuously administered, according to the dosing schedule chosen, until the desired therapeutic effect is achieved, i.e. up to the time that the clinical or medical effect sought for the disease or condition being treated is observed by the clinician or researcher. For methods of treatment of the present invention, the NK-1 receptor antagonist and any additional active agent(s) should be continuously administered until the desired change in bone resorption rate, bone mass, or bone structure is observed. In such instances, achieving an increase in bone mass or a replacement of abnormal bone structure with normal bone structure are the desired objectives. For methods of prevention of the present invention, the NK-1 receptor antagonist and any additional active agent(s) should be continuously administered for as long as necessary to prevent the undesired condition.
In such instances, maintenance of existing bone mass is often the objective. Non-limiting examples of administration periods can range from about 2 weeks to the remaining lifespan of the mammal. For humans, administration periods can range from about 2 weeks to the remaining lifespan of the human, preferably from about 2 weeks to about 20 years, more preferably from about 1 month to about 20 years, more preferably WO 00/07598 PCT/GB99/02509 -8from about 6 months to about 10 years, and most preferably from about 1 year to about 10 years.
The term "mammal" as used herein include animals of economic importance such as bovine, ovine, and porcine animals, especially those that produce meat, as well as domestic animals, sports animals, zoo animals, and humans, the latter being preferred.
The compositions of the present invention are especially useful for the treatment or prevention of abnormal bone resorption where the use of a bisphosphonate or estrogen replacement therapy is generally prescribed.
By the use of a NK-1 receptor antagonist, optionally in combination with one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones in accordance with the present invention, it is now also possible to treat or prevent abnormal bone resorption in patients for whom conventional therapy might not be wholly successful or where patient compliance with existing therapeutic regimens is problematic.
NK-1 receptor antagonists of use in the present invention are described in published European Patent Specification Nos. 0 360 390, 0 394 989, 0 429 366, 0 443 132, 0 482 539, 0 512 901, 0 512 902, 0 514 273, 0 514 275, 0 517 589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0 545 478, 0 577 394, 0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 714 891, 0 723 959, 0 733 632 and 0 776 893; and in International Patent Specification Nos. 90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 93/00330, 93/00331, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116, 93/10073, 93/14113, 93/18023, 93/19064, 93/21155, 9321181, 93/23380, 93/24465, 94/01402, 94/02461, 94/03429, 94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639, 94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740, WO 00/07598 -9- 94/29309, 95/02595, 95/04040, 95/04042, 95/06645, 95/08549, 95/11880, 95/14017, 95/15311, 95/16679, 95/18129, 95/19344, 95/20575, 95/21819, 96/22525, 95/28418, 95/30674, 95/30687, 96/05193, 96/05203, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489, 97/03066, 97/08144, 97/14671, 97/17362, 97/18206, 97/21702, 97/22597, 97/24350, 97/30055, 97/38692, PCT/GB99/02509 95/07886, 95/07908, 95/17382, 95/18124, 95/23798, 95/26338, 96/06094, 96/07649, 96/29304, 96/29317, 97/01553, 97/01554, 97/19084, 97/19942, 97/49710, 98/01450, 98/13369, 98/49170, 98/54187, 99/00368 and 99/24423; and in British Patent Specification Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168, 2 293 169, 2 302 689, 2 309 458 and 2 321 058.
Particularly preferred NK-1 receptor antagonists are those described in European Patent Specification No. 0 577 394, especially compounds of formula x
R
4
(I)
R- N R
R
or a pharmaceutically acceptable salt thereof, wherein:
R
1 is selected from the group consisting of: C1-6alkyl, substituted with one or more of the substituents selected from: heterocycle, wherein the heterocycle is selected from the group consisting of: benzimidazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrazinyl, WO 00/07598 PCT/GB99/02509 pyrazolyl, pyridyl, pyrrolyl, tetrazolyl, thiadiazolyl, triazolyl, and piperidinyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from: Ci-6alkyl, unsubstituted or substituted with halo, -CF 3
-OCH
3 or phenyl, (ii) Cl-6alkoxy, (iii) oxo, (iv) thioxo, cyano, (vi) -SCH3, (vii) phenyl, (viii) hydroxy, (ix) trifluoromethyl,
-(CH
2 )m-NR 9
R
1 0 wherein m is 0, 1 or 2, and R 9 and Ro 1 areindependently selected from: hydrogen, (II) CI-6alkyl, (III) hydroxyCl-6alkyl, and (IV) phenyl, (xi) -NR 9
COR'
1 wherein R 9 and R' 1 are as defined above, and (xii) -CONR 9 R'O, wherein R 9 and RI' are as defined above,
R
2 and R 3 are independently selected from the group consisting of: hydrogen; Ci-ealkyl WO 00/07598 PCT/GB99/02509 C2-6alkenyl, and phenyl; X is
R
4 is R 7 z R8
R
5 is phenyl, unsubstituted or substituted with halo;
R
6
R
7 and R 8 are independently selected from the group consisting of: hydrogen, CI-6alkyl, halo, and
-CF
3 Y is and Z is hydrogen or C1-4alkyl; and pharmaceutically acceptable salts thereof.
Particularly preferred compounds of formula are: 1,2,4-triazolo)methyl)-2(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(S)phenyl-morpholine; 1,2,4-triazolo)methyl)-2(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(R)phenyl-morpholine; 4-(3-(5-oxo- 1H,4H-1,2,4-triazolo)methyl)-2(S)-(3 bis(trifluoromethyl)benzyloxy)-3(S)-phenyl-morpholine; and ,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 5-oxo- 1H,4H- 1,2,4-triazolo)methyl)morpholine; or a pharmaceutically acceptable salt thereof.
Further preferred NK-1 receptor antagonists are those described in International (PCT) Patent Specification No. WO 95/18124, especially compounds of formula (ID) and pharmaceutically acceptable salts thereof.
WO 00/07598 PCT/GB99/02509 -12-
A
1
YI
O O A 2 KN A R A 3
(II)
wherein:
A
1 is fluorine or CF 3
A
2 is fluorine or CF 3
A
3 is fluorine or hydrogen;
R
6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =S or a C1-4alkyl group, and optionally substituted by a group of the formula ZNR 7 R where Z is Cl.1alkylene or C3.6cycloalkylene;
R
7 is hydrogen, C1- 4 alkyl, C3.7cycloalkyl or C3-7cycloalkylC1.4alkyl, or C2- 4 alkyl substituted by CI-4alkoxy or hydroxyl;
R
8 is hydrogen, C.- 4 alkyl, C3a7cycloalkyl or C3-7cycloalkylC1-4alkyl, or C2- 4 alkyl substituted by one or two substituents selected from C1.4alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S; or R 7
R
8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by a hydroxy group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(0) or S(0)2 or a second nitrogen atom which will be part of a NH or NRc moiety where Rc is C1- 4 alkyl optionally substituted by hydroxy or C1.4alkoxy; or R 7
R
8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms; WO 00/07598 PCT/GB99/02509 -13or Z, R 7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo; and Y is a C1-4alkyl group optionally substituted by a hydroxyl group; with the proviso that if Y is C1-4alkyl, R 6 is susbstituted at least by a group of formula ZNR 7
R
8 as defined above.
Particularly preferred compounds of formula (II) include: 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino) methyl-l,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino) methyl-l,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine; 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine; and pharmaceutically acceptable salts thereof.
Further preferred NK-1 receptor antagonists are those described in European Patent Specification No. WO 95/23798, especially compounds of formula (III): R X 7 Z Z R
(III)
I R (0)P
A
(O)p A S 12 B R 3 or a pharmaceutically acceptable salt thereof, wherein:
R
2 and R 3 are independently selected from the group consisting of: hydrogen, Ci- 6 alkyl,
C
2 -6alkenyl, and WO 00/07598 PCT/GB99/02509 -14phenyl;
R
6
R
7 and R 8 are independently selected from the group consisting of: hydrogen, Ci-6alkyl, fluoro, chloro, bromo, iodo, and
-CF
3
R
11
R
12 and R 13 are independently selected from the group consisting of: fluoro, chloro, bromo, and iodo; A is unsubstituted 1-6alkyl; B is selected from the group consisting of: N-N X H X N- ,X H X\ H N-N N-N N-N N o o SN 0 N N X
H
H
X
N-N H X N-N N-N N-N N S N S X ,X I N N 0 S X H N X N-N N N-N
N
N N
N
N X X WO 00/07598 WO 0007598PCT/GB99/02509 15 x
N
H
N
x N 0 x
H
N
N 0 x
N
N
S
H
H
1
N
N
S"
p is 0ocr 1; X is selected from: -PO(OH)0- wherein M' is a pharmaceutically acceptable monovalent counterion,
-PO(O-)
2 *2M+, -PO(0-) 2
D
2 wherein D 2 is a pharmaceutically acceptable divalent counterion, -CH(R4)-PO(OH)0- wherein R4 is hydrogen or CI3alkyl, Wi -CO-CH 2
CH
2 -C0 2 0
-CH(CH
3 )-O-CO-R5, wherein R 5 is selected from the group consisting of: WO 00/07598 WO 0007598PCT/GB99/02509 16
H
2
M-
(ii) OH (iii) (iv)
(M
(vi) (vii) 0 C02M+ 0N~ C0 2 M 0 Y C0 2
NH
3 0
CO,-
and Y is Z is hydrogen or C1l6alkyl; and pharmaceutically acceptable salts thereof.
Particularly preferred compounds of formula (III) include: ,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(5-oxo- 1H,4H- 1,2,4-triazolo)methyl)morpholine N-oxide; WO 00/07598 PCT/GB99/02509 17 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(4- (ethoxycarbonyloxy- 1-ethyl)-5-oxo-1H- 1,2,4triazolo)methyl)morpholine; 1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4fluorophenyl)-4-(3-(4-monophosphoryl-5-oxo-1H- 1,2,4triazolo)methyl)morpholine; ,5-bis(trifiuoromethyl)phenyl )ethoxy)-3-(S)-(4fluorophenyl)-4-(3-( 1-monophosphoryl-5-oxo-1H- 1,2,4triazolo)methyl)morpholine; ,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S fiuorophenyl)-4-(3-(2-monophosphoryl-5-oxo- 1H-1 ,2 ,4triazolo)methyl)morpholine; 1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-( fluorophenyl)-4-(3-(5-oxyphosphoryl- 1H- 1,2,4triazolo)methyl)morpholine; ,5-bis(trifluoromethyl)phenyl )ethoxy)-3-(S)-(4fluorophenyl)-4-(3-( 1-monophosphoryl-5-oxo-4H- 1,2,4triazolo)methyl )morpholine; and pharmaceutically acceptable salts thereof.
Further preferred NK-1 receptor antagonists are those described in International Patent Specification No. WO 97/49710, especially compounds of formula (IV) R I Rk 0-
(IV)
H1 wherein WO 00/07598 PCT/GB99/02509 18 RI represents hydrogen, hydroxy, Cl-6alkyl, C2-6alkenyl, C3.7cycloalkyl, C3-7CYCloalkylC l.4alkyl, C 1 6alkoxy, fluoroC 1-6alkoxy, C l-6alkoxyC l.4alkyl, CI-6alkoxyCl- 4 alkoxy, fluoroC l.6alkoxyC 1-4alkyl, C2-6alkenyloxy, C3-7cycloalkoxy, C3-7cycloalkylCl- 4 alkoxy, phenoxy, benzyloxy, cyano, halogen, NRaRb, SRa, SORa, SO 2 Ra, OSO 2 Ra, NRaCOR14, CORa, CO 2 Ra or CONRaRb where Ra and Rb each independently represent hydrogen, C1v4alkyl or fluoroCl.4alkyl;
R
2 represents hydrogen, halogen, Cp-6alkyl or C1.6alkoxy; or RI and R 2 may be joined together such that there is formed a 5- or 6-membered saturated or unsaturated ring containing one or two atoms selected from nitrogen, oxygen and sulphur, which ring is optionally substituted by a group selected from C1a 4 alkyl, CF3, =0 or=S
R
3 represents hydrogen, halogen, C 1-6alkyl, fluoroC l6alkyl, C 1-6alkoxy, fluoroC 1-alkoxy, C3-7cycloalkyl, C3-7cycloalkylCla4alkyl, cyano, SRa, SORa, SO 2 Ra, NRaRb, NRaCORI4, CORa, C0 2 Ra, CONRaRb or C14alkyl substituted by cyano, C0 2 Ra or CONRaRb where Ra and Rb are as previously defined; R4 represents hydrogen, halogen, C1v6alkyl, C1-6alkoxy, CF 3
OCF
3 N0 2 CN, SRa, SORa, SO 2 Ra, CO 2 Ra, CONRaRb, C2.6alkenyl, C2.6alkynyl or C1v 4 alkyl substituted by Ci-4alkoxy, where Ra and Rb are as previously defined; and the broken line represents an optional double bond; and pharmaceutically acceptable salts thereof.
Particularly preferred compounds of formula (IV) include: (3R ,5R,68)-3-(2-methoxy-5-(trifluoromethoxy)phenyl)-6-phenyl- 1-oxa-7aza-spiro decane; (3R ,5R,6S)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-6-phenyl-1-oxa-7-azaspiro ,6S)-7-benzyl [2-methoxy-5-(trifluoromethoxy)phenyl] -6-phenyl- 1oxa-7-aza-spiro[4.5ldecane; (3R, 51?,6S)-3-(2-methoxy-5-trifluorornethoxyphenyl)-6-phenyl- 1-oxa- 7 -aza- 19 spiro decane; (3R,SR ,6S)-3 ,6-bis(phenyl )-l1-oxa-7-aza-spiro [4.51 decane; (3R ,5R,6S)-7-benzyl-3-(2-methoxy-5-trifluoromethoxyphenyl)-6-phenyl-1..
oxa-7-aza-spiro[4.51 decane; *,5R*,6S*)..3.(2..methoxyphenyl).6phenyl-..oxa.7.
(phenylmethoxycarbonyl)aza-spiro [4.51 decane; (3R,5R,6S)-3-(2-methoxyphenyl)-6-phenyl-1-oxa-7-aza-spiro[4.5] decane; (3S, 5R,6S)-3-(2-cyclopropoxy-5-(tifluoromethoxy)phenyl)-6-phenyl- 1-oxa- 7-aza-spiro[4.51 decane; (3R, 5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl] -6-phenyl-1-oxa- 7-aza-spiro [4.51 decane; (3S, 5R,6S [2-cyclopropoxy-5-(trifluoromethyl)pheny] -6-phen~yl-1 -oxa-7aza-spiro decane; and pharmaceutically acceptable salts thereof.
Another class of NK-1 receptor antagonists of use in the present disclosure is that described in European Patent Specification No.
0 436 334, i.e. compounds of formula
RI
I R3
V)
R (1 16
R
or a pharmaceutically acceptable salt thereof, wherein Y is WCHO. wherein n is an integer from 1 to 4, and wherein any one of the carbon-carbon single bonds in said (CH 2 may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbon atoms of said WCHO. may optionally be substituted with R 4 and wherein any one of the carbon atoms of said (CH 2 may optionally be substituted with R 7 WO 00/07598 PCT/GB99/02509 Z is (CH2)m wherein m is an integer from 0 to 6, and wherein any one of the carbon-carbon single bonds of (CH2)m may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said (CH 2 )m may optionally be substituted with
R
8
R
1 is hydrogen or Cl-salkyl optionally substituted with hydroxy, C1-4alkoxy or fluoro;
R
2 is a radical selected from hydrogen, C 1 -6 straight or branched alkyl, C3-7cycloalkyl wherein one of the CH 2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulphur; aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl-C2-6alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl C2-6alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, C1-6 alkyl, C1-6alkoxy, trifluoromethyl, amino, Cli6alkylamino, Cli-alkyl-O-CO, CI.6alkyl-O-CO- C1-6alkyl, Cl-6alkyl-CO-O, CI-6alkyl-CO-Ci-6alkyl-O-, Cl-6alkyl-CO,
C.I
6 alkyl-CO-C1-6alkyl-, di-CI.-alkylamino, -CONH-Cl-6alkyl, C l-alkyl-CO-NH-CI-6alkyl, -NHCOH and -NHCO-Cl.6alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;
R
5 is hydrogen, phenyl or Cli6alkyl; or R 2 and R 5 together with the carbon to which they are attached, form a saturated ring having from 3 to 7 carbon atoms wherein one of the
CH
2 groups in said ring may optionally be replaced by oxygen, NH or sulfur;
R
3 is aryl selected from phenyl and naphthyl; heteroaryl selected from indanyl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; and cycloalkyl having 3 to 7 WO 00/07598 PCT/GB99/02509 -21carbon atoms wherein one of the (CH 2 groups in said cycloalkyl may optionally be replaced by NH, oxygen or sulphur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said C3-acycloalkyl may optionally be substituted with one or two substituents, each of said substituents being independently selected from halo, nitro, CI-6alkyl, C-.6alkoxy, trifluoromethyl, amino, Ci.-alkylamino, -CO-NH- C1.6alkyl, C1-6alkyl-CO-NH-CI-6alkyl, -NHCOH and -NHCO-Ci-6alkyl;
R
4 and R 7 are each independently selected from hydroxy, halogen, halo, amino, oxo, cyano, methylene, hydroxymethyl, halomethyl, Cl-6alkylamino, di-Ci.-alkylamino, Ci-6alkoxy, C-.6alkyl-O-CO, C1-6alkyl-O-CO-C1-6alkyl, C-6alkyl-CO-O, C1-6alkyl-CO-C.-6alkyl-O-, C1.6alkyl-CO-, C-.6alkyl-CO-CI.6alkyl, and the radicals set forth in the definition of R 2
R
6 is -NHCOR 9
-NHCH
2
R
9 S0 2
R
8 or one of the radicals set forth in any of the definitions of R 2
R
4 and R 7
R
8 is oximino (=NOH) or one of the radicals set forth in any of the definitions of R 2
R
4 and R 7
R
9 is Cl-6alkyl, hydrogen, phenyl or phenylCl-6alkyl; with the proviso that when m is 0, R 8 is absent, when R 4
R
6
R
7 or
R
8 is as defined in R 2 it cannot form together with the carbon to which it is attached ,a ring with R 5 and when R 4 and R 7 are attached to the same carbon atom, then either each of R 4 and R 7 is independently selected from hydrogen, fluoro and Cl-6alkyl, or R 4 and R 7 together with the carbon to which they are attached, for a C3-6 saturated carbocyclic ring that forms a spiro compound with the nitrogen-containing ring to which they are attached.
A particularly preferred compound of formula is (2S,3S)-cis-3-(2methoxybenzylamino)-2-phenylpiperidine; or a pharmaceutically acceptable salt thereof.
-22- Another class of NK-1 receptor antagonists of use in the present disclosure is that described in International Patent Specification No. WO 93/21155, i.e. compounds of formula (VI): R R 0
R
CH--R
1 (vI)
R
3
R
4 or a pharmaceutically acceptable salt thereof, wherein radicals R are phenyl radicals optionally 2- or 3-substituted by a halogen atom or a methyl radical;
R
I is optionally substituted phenyl, cyclohexadienyl, naphthyl, indenyl or optionally substituted heterocycle;
R
2 is H, halogen, OH, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkyloxy, alkylthio, acyloxy, carboxy, optionally substituted alkyloxycarbonyl, benzyloxycarbonyl, amino or acylamino;
R
3 is optionally 2-substituted phenyl;
R
4 is OH or fluorine when R 5 is H; or R 4 and R 5 are OH; or R 4 and R 5 together form a bond.
A particularly preferred compound of formula (VI) is (3aS, 4S, 7aS)- 7,7-diphenyl-4-(2-methoxyphenyl)-2-[(2S)-(2-methoxyphenyl)propionyl] perhydroisoindol-4-ol; or a pharmaceutically acceptable salt thereof.
Another class of NK-1 receptor antagonists of use in the present disclosure is that described in European Patent Specification No.
0 591 040, i.e. compounds of formula (VII): R
Q
Ar-T-CO-N-CH 2
-C-CH
2
-CH
2 -Am A (VII) Ar' wherein -23- Ar represents an optionally substituted mono-, di- or tricyclic aromatic or heteroaromatic group; T represents a bond, a hydroxymethylene group, a Cl-4alkoxymethylene group or a C1-salkylene group; Ar' represents a phenyl group which is unsubstituted or substituted by one or more substituents selected from halogen, preferably chlorine or d fluorine, trifluoromethyl, C1-4alkoxy, Ci-4alkyl where the said substituents may be the same or different; a thienyl group; a benzothienyl group; a naphthyl group; or an indolyl group; R represents hydrogen, C-4alkyl, o-C1-4alkoxyC1-4alkyl, or o-C 2 -4alkanoyloxyC2-4alkyl; Q represents hydrogen; or Q and R together form a 1,2-ethylene, 1,3-propylene or 1,4butylene group; Am* represents the radical 213 in which X 1
X
2 and X 3 together with the nitrogen atom to which they are attached, form an azabicyclic or azatricyclic ring system optionally substituted by a phenyl or benzyl group; and 20 A- represents a pharmaceutically acceptable anion.
A particularly preferred compound of formula (VII) is (3,4-dichlorophenyl)-1-[(3-isopropoxyphenyl)acetyl]-3-piperidinyl] ethyl] -4phenyl-l-azabicyclo[2,2,2]octane; or a pharmaceutically acceptable salt, especially the chloride, thereof.
Another class of NK-1 receptor antagonists of use in the present disclosure is that described in European Patent Specification No.
0 532 456, i.e. compounds of formula (VIII): -24-
R
j R -N 4
(VIII)
.R-Xi or a pharmaceutically acceptable salt thereof, wherein
R
1 represents an optionally substituted aralkyl, aryloxyalykl, heteroaralkyl, aroyl, heteroaroyl, cycloalkylcarbonyl, aralkanoyl, heteroarylalkanoyl, aralkoxycarbonyl or arylcarbamoyl group or the acyl group of an a-amino acid optionally N-substituted by a lower alkanoyl or carbamoyl-lower alkanoyl group;
R
2 represents cycloalkyl or an optionally substituted aryl or heteroaryl group;
R
3 represents hydrogen, alkyl, carbamoyl or an alkanoyl or alkenoyl group optionally substituted by carboxy or esterified or amidated carboxy;
R
4 represents an optionally substituted aryl group or an optionally partially saturated heteroaryl group; Xi represents methylene, ethylene, a bond, an optionally ketalised carbonyl group or an optionally etherified hydroxymethylene group;
X
2 represents alkylene, carbonyl or a bond; and
X
3 represents carbonyl, oxo-lower alkyl, oxo(aza)-lower alkyl, or an alkyl group optionally substituted by phenyl, hydroxymethyl, optionally esterified or amidated carboxy, or (in other than the a-position) hydroxy.
20 A particularly preferred compound of formula (VIII) is 4S*)-2benzyl-l-(3,5-dimethylbenzoyl)-N-( 4 -quinolinylmethyl)-4-piperidineamine; or a pharmaceutically acceptable salt thereof.
Another class of NK-1 receptor antagonists of use in the present disclosure is that described in European Patent Specification No.
0 443 132, i.e. compounds of formula (IX) $*eo WO 00/07598 PCT/GB99/02509
CH,
R
4
R
1 -Y-A-N CONHCHCON (IX) or a pharmaceutically acceptable salt thereof, wherein
R
1 is aryl, or a group of the formula: z X is CH or N; and Z is O or N-R 5 in which R 5 is hydrogen or lower alkyl;
R
2 is hydroxy or lower alkoxy;
R
3 is hydrogen or optionally substituted lower alkyl;
R
4 is optionally substituted ar(lower)alkyl; A is carbonyl or sulfonyl; and Y is a bond or lower alkenylene.
A particularly preferred compound of formula (IX) is the compound of formula (IXa)
HO
I I (IXa)
N-
H
3
C
or a pharmaceutically acceptable salt thereof.
-26- Another class of NK-1 receptor antagonists of use in the present disclosure is that described in International Patent Specification No. WO 92/17449, i.e. compounds of the formula (X) H
R
r..z v
R
or a pharmaceutically acceptable salt thereof, wherein
R
1 is aryl selected from indanyl, phenyl and naphthyl; heteroaryl selected from thienyl, furyl, pyridyl and quinolyl; and cycloalkyl having 3 to 7 carbon atoms, wherein one of said carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said C3s.cycloalkyl may optionally be substituted with one or two substituents, said substituents being independently selected from chloro, fluoro, bromo, iodo, nitro, Ci-ioalkyl optionally substituted with from one to three fluoro groups, Ci-loalkoxy optionally substituted with from one to three fluoro groups, amino, Ci-loalkyl-S-, Ci-ioalkyl-S(O)-, Ci-ioalkyl-S02-, phenyl, phenoxy, C1-loalkyl-SO 2
NH-,
Ci-loalkyl-SO2NH-Ci-ioakyl-, Ci-ioalkylamino-diC1i.oalkyl-, cyano, hydroxy, cycloalkoxy having 3 to 7 carbon atoms, Cl-6alkylamino, Cl-6dialkylamino, HC(O)NH- and Ci-loalkyl-C(O)NH-; and 20 R 2 is thienyl, benzhydryl, naphthyl or phenyl optionally substituted with from one to three substituents independently selected from chloro, bromo, fluoro, iodo, cycloalkoxy having 3 to 7 carbon atoms, C1-1oalkyl optionally substituted with from one to three fluoro groups and Ci-ioalkoxy optionally substituted with from one to three fluoro groups.
A particularly preferred compound of formula is (2S,3S)-3-(2methoxy-5-trifluoromethoxybenzyl)-amino-2-phenylpiperidine; or a pharmaceutically acceptable salt thereof.
-27- Another class of NK-1 receptor antagonists of use in the present disclosure is that described in International Patent Specification No.
WO 95/08549, i.e. compounds of formula (XI)
R
2
(CH
2 )x
H
N R 3 H R 4
(XI)
or a pharmaceutically acceptable salt thereof, wherein
R
1 is a C1.4alkoxy group;
R
2 is 6
N
N-N
R
3 is a hydrogen or halogen atom;
R
4 and R 5 may each independently represent a hydrogen or halogen atom, or a C1-4alkyl, C1-4alkoxy or trifluoromethyl group; R6 is a hydrogen atom, a Ci-4alkyl, (CH2)mcyclopropyl, S(O)nC-4alkyl, phenyl, NR 7
R
8
CH
2
C(O)CF
3 or trifluoromethyl group;
R
7 and R 8 may each independently represent a hydrogen atom, or a Cl4alkyl or acyl group; x represents zero or 1; n represents zero, 1 or 2; and m represents zero or 1.
Particularly preferred compounds of formula (XI) are 20 tetrazol-1-yl-benzyl)-([2S,3S]-2-phenyl-piperidin-3-yl)-amine; and [2methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-([2S,3S]-2-phenylpiperidin-3-yl)-amine; or a pharmaceutically acceptable salt thereof.
28 Another class of tachykinin antagonists of use in the present disclosure is that described in International Patent Specificat ion No.
WO 95/14017, i.e. compounds of formula (XII) R8 R4 1 1 R-(CH )R 3 NHi R
(OH
2 1 1 (XII) or a pharmaceutically acceptable salt thereof, wherein mn is zero, 1, 2 or 3; n is zero or 1;o is zero, Ilor 2; p is zero or 1; R is phenyl, 2- or 3-indolyl, 2- or 3-indolinyl, benzothienyl, benzofuranyl, or naphthyl; which R groups may be substituted with one or two halo, CI.3alkoxy, trifluoromethyl, C 14alkyl, phenyl-C 1.3alkoxy, or C 1-4alkanoyl groups; RI is trityl, phenyl, diphenylmethyl, phenoxy, phenylthio, 15 piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, indolinyl, indolyl, benzothienyl, hexamethyleneiminyl, benzofuranyl, tetrahydropyridinyl, quinolinyl, isoquinolinyl, reduced quinolinyl, reduced isoquinolinyl, phenyl-(CI- 4 alkyl)-, phenyl-(Ci~alkoxy)-, quinolinyl-(Cl 4 alkyl)-, isoquinolinyl-(Cl~alkyl)-, reduced quniolinyl-(Ci-4alkyl)-, reduced isoquinolinyl-(Cl-4alkyl)-, benzoyl-(C 1-3alkyl)-, C 1.4alkyl, or -NH-CH 2 any one of which RI groups may be substituted with halo, C14alkyl, C14alkoxy, trifluoromethyl, amino, Ci-4alkylamino, di(CI-4alkyl)amino, or C2-4alkanoylamino; or any one of which RI groups may be substituted with phenyl, 25 piperazinyl, C3-SCYCloalkyl, benzyl, C 14alkyl, piperidinyl, pyridinyl, .9.9 99 S 9.9.
9.
*9 *9
S
9 *990 9.
99 9
S
99 .9 9. 9 9 .99 99 99 S 9 9 9.
S 9 @999 @9 9 99
S.
WO 00/07598 PCT/GB99/02509 29 pyrimidinyl, C 2 6alkanoylamino, pyrrolidinyl, C2-6alkanoyl, or C I 4 alkoxycarbonyl; any one of which groups may be substituted with halo, CI-4alkyl, C1.
4 alkoxy, trifluoromethyl, amino, C1.4alkylamino, di(CI-4alkyl)amino, or C2 4 alkanoylamino; or RI is amino, a leaving group, hydrogen, Cl-4alkylamino, or di(C 1-4alkylbamino;
R
5 is pyridyl, anilino-(C 1-3alkyl or anilinocarbonyl;
R
2 is hydrogen, C 1.4alkyl, C 1-4alkylsulfonyl, carboxy-(C 1-3alkyl)-, Cl.
3 alkoxycarbonyl-(CI-3alkyl)-, or -CO-R 6
R
6 is hydrogen, C1- 4 alkyl, CI-3haloalkyl, phenyl, C1iaalkoxy, Cl-3hydroxyalkyl, amino, CI-4alkylamino, di(Cli 4 alkyl)amino, or -(CH2)q-R 7 q is zero to 3;
R
7 is carboxy, Cl-4alkoxycarbonyl, Cl4alkylcarbonyloxy, amino, Cl.4alkylamino, di(Cli 4 alkyl)amino, C1.6alkoxycarbonylamino, or phenoxy, phenylthio, piperazinyl, piperidinyl, pyrroli dinyl, morpholinyl, indolinyl, indolyl, benzothienyl, benzofuranyl, quinolinyl, phenyl-(C 1-4alkyl)-, quinolinyl-(Cl-4alkyl)-, isoquinolinyl-(Ca-4alkyl)-, reduced quinolinyl- (Cl-4alkyl)-, reduced isoquinolinyl-(C1.4alkyl)-, benzoyl-C l3alkyl; any one of which aryl or heterocyclic R 7 groups may be substituted with halo, trifluoromethyl, C 1-4alkoxy, C 14alkyl, amino, C l4alkylamino, di(C 1-4alkyl)amino, or C2-4akanoylamino; or any one of which R 7 groups may be substituted with phenyl, piperazinyl, C 3 8CYCloalkyl, benzyl, piperidinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, C26alkanoyl, or Cl-4alkoxycarbonyl; any of which groups may be substituted with halo, trifluoromethyl, amino, C 1 4 alkoxy, C1- 4 alkyl, Cl.4alkylamino, di(CI- 4 alkyl)amino, or C2- 4 alkanoylamino;
R
8 is hydrogen or C1p6alkyl;
R
3 is phenyl, phenyl-(C-6alkyl)-, C3.8cycloalkyl, C 5 .scycloalkenyl, Ci-8alkyl, naphthyl, C2-8alkenyl, or hydrogen; WO 00/07598 PCT/GB99/02509 any one or which groups except hydrogen may be substituted with one or two halo, C1.3alkoxy, C1-3alkylthio, nitro, trifluoromethyl, or C1-3alkyl groups; and
R
4 is hydrogen or C1.-alkyl; with the proviso that if R 1 is hydrogen or halo, R 3 is phenyl, phenyl-(CI-6alkyl)-, C3-scycloalkyl, Cs.5cycloalkenyl, or naphthyl.
A particularly preferred compound of formula (XII) is methoxybenzyl)acetylamino]-3-(1H-indol-3-yl)-2-[N-(2-(4-piperidin-1yl)piperidin-l-yl)acetylamino] propane; or a pharmaceutically acceptable salt thereof.
The bisphosphonates of use in the present invention correspond to the chemical formula (XIII)
PO
3 H2
A-C-X
PO
3
H
2
(XIII)
wherein A and X are independently selected from the group consisting of H, OH, halogen, NH 2 SH, phenyl, C 1 -Cao alkyl, Ca-C 30 cycloalkyl, C 1
-C
3 0 substituted alkyl, Ca-C30 substituted cycloalkyl, C 1 -Clo alkyl or C 3
-C
1 o cycloalkyl mono- or di- substituted NH 2
C
1
-C
1 o alkoxy, Ci-Clo alkyl or
C
3 -Clo cycloalkyl substituted thio, phenyl substituted thio, C 1 -Cio alkyl or
C
3
-C
10 cycloalkyl substituted phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, and benzyl.
In the foregoing chemical formula (XIII), the alkyl groups can be straight or branched. The C 1 -C30 substituted alkyl and C 3
-C
3 0 substituted cycloalkyl can include a wide variety of substituents, nonlimiting examples which include those selected from the group consisting of phenyl, pyridyl, WO 00/07598 PCT/GB99/02509 -31furanyl, pyrrolidinyl, imidazonyl, NH 2
C
1 -Clo alkyl or C 3
-C
10 cycloalkyl mono- or di- substituted NH 2 OH, SH, and Ci-Co alkoxy.
In the foregoing chemical formula (XIII), A can include X and X can include A such that the two moieties can form part of the same cyclic structure.
The foregoing chemical formula (XIII) is also intended to encompass complex carbocyclic, aromatic and hetero atom structures for the A and/or X substituents, nonlimiting examples of which include naphthyl, quinolyl, isoquinolyl, adamantyl, and chlorophenylthio.
Preferred compounds of formula (XIII) are those in which A is selected from the group consisting of H, OH, and halogen, X is selected from the group consisting of C 1
-C
3 0 alkyl, C3-C 30 cycloalkyl, C 1 substituted alkyl, C 3
-C
30 substituted cycloalkyl, halogen, Ci-Clo alkyl or
C
3 -Co 1 cycloalkyl substituted thio, and phenyl substituted thio.
Particularly preferred compounds of formula (XIII) are those in which A is selected from the group consisting of H, OH, and Cl, and X is selected from the group consisting of C 1
-C
3 0 alkyl, C 3
-C
3 0 cycloalkyl, C 1
-C
30 substituted alkyl, C 3
-C
3 0 substituted cycloalkyl, C1, and chlorophenylthio.
Most preferred is when A is OH and X is 4-aminobutyl, i.e.
alendronate.
Non-limiting examples of bisphosphonates useful herein include the following: Alendronic acid, 4-amino-l-hydroxybutylidene-1,1-bisphosphonic acid.
Alendronate (also known as alendronate sodium or monosodium trihydrate), 4-amino-l-hydroxybutylidene-l,l-bisphosphonic acid monosodium trihydrate.
Alendronic acid and alendronate are described in U.S. Patents 4,922,007, to Kieczykowski et al., issued May 1, 1990, and 5,019,651, to Kieczykowski, issued May 28, 1991, both of which are incorporated by reference herein in their entirety.
WO 00/07598 PCT/GB99/02509 -32- Cycloheptylaminomethylene-l,l-bisphosphonic acid, YM 175, Yamanouchi (cimadronate), as described in U.S. Patent 4,970,335, to Isomura et al., issued November 13, 1990, which is incorporated by reference herein in its entirety.
1,1-dichloromethylene-1,1-diphosphonic acid (clodronic acid), and the disodium salt (clodronate, Procter and Gamble), are described in Belgium Patent 672,205 (1966) and J. Org. Chem 32, 4111 (1967), both of which are incorporated by reference herein in their entirety.
1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonic acid (EB-1053).
1-hydroxyethane-l,l-diphosphonic acid (etidronic acid).
1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-l,1bisphosphonic acid, also known as BM-210955, Boehringer-Mannheim (ibandronate), is described in U.S. Patent No. 4,927,814, issued May 22, 1990, which is incorporated by reference herein in its entirety.
6-amino- -hydroxyhexylidene-1,1-bisphosphonic acid (neridronate).
3-(dimethylamino)-l-hydroxypropylidene-1,1-bisphosphonic acid (olpadronate).
3-amino-l-hydroxypropylidene-1,1-bisphosphonic acid (pamidronate).
[2-(2-pyridinyl)ethylidene]-l,l-bisphosphonic acid (piridronate) is described in U.S. Patent No. 4,761,406, which is incorporated by reference in its entirety.
1-hydroxy-2-(3-pyridinyl)-ethylidene-1,1-bisphosphonic acid (risedronate).
(4-chlorophenyl)thiomethane-1,1-disphosphonic acid (tiludronate) as described in U.S. Patent 4,876,248, to Breliere et al., October 24, 1989, which is incorporated by reference herein in its entirety.
WO 00/07598 PCT/GB99/02509 -33- 1-hydroxy-2-(1H-imidazol- 1-yl)ethylidene-1,1-bisphosphonic acid (zoledronate).
Preferred are bisphosphonates selected from the group consisting of alendronate, cimadronate, clodronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
More preferred is alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
Most preferred is alendronate monosodium trihydrate.
Estrogen receptor modulators are known for use in hormone replacement therapy and for their anti-bone resorption benefits.
Nonlimiting examples of estrogen receptor modulators useful herein include estrogen, progestins, estradiol, raloxifene, and tamoxifene, and their pharmaceutically acceptable salts, and mixtures thereof.
Further examples of estrogen receptor modulators include clometherone, delmadinone, droloxifene, idoxifene, nafoxidine, nitromifene, ormeloxifene (centchroman), toremifene, trioxifene, BE-25327, CP-336156 and ([2-(4-hydroxyphenyl)-6-hydroxynaphthalen- 1yll -piperidinyl)ethoxy]phenyl]methane, and their pharmaceutically acceptable salts, and mixtures thereof.
Non-limiting examples of an androgen receptor modulators include danazol, 5a-dihydrotestosterone, testosterone, nandrolane decanoate, methyltestosterone, methanadrostenolone, stanozolol, fluoxymesterone, oxymetholone, oxandrolone, oxymethol, norethandrolone, ethylestranol, 4-androsten-19-al-3,17-dione, 19-nortestosterone, norethandrone, norethisterone, dehydroepiandrosterone, epiandrosterone sulfate, androstenedione and androstenediol, testosterone propionate, testosterone cytpionate, and testosterone enanthate.
A peptide hormone useful herein is calcitonin, which is approved for use for treating osteoporosis. Both human and salmon calcitonin are useful herein.
WO 00/07598 PCT/GB99/02509 -34- The preferred compounds of formulae (II) and (III) will have the 2- and 3-substituents on the morpholine ring in the cis arrangement, the preferred stereochemistry being as shown in the following general formula: O0 1 2 N i
R
Where the benzyloxy moiety is a-substituted, the preferred stereochemistry of the a-carbon is either when the substituent is an alkyl methyl) group or when the substituent is a hydroxyalkyl hydroxymethyl) group.
The preferred compounds of formula (IV) will have the stereochemistry of the 5- and 6-positions as shown below Where the optional double bond shown in formula (IV) is absent, the particularly preferred compounds will have the stereochemistry of the 3-position as shown below 0 N
H
Unless otherwise defined herein, suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straightchained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl and tert-butyl.
WO 00/07598 PCT/GB99/02509 Unless otherwise defined herein, suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.
Unless otherwise defined herein, suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.
Unless otherwise defined herein, suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.
Unless otherwise defined herein, suitable aryl groups include phenyl and naphthyl groups.
A particular aryl-C.(;alkyl, e.g. phenyl-Ci-,alkyl, group is benzyl.
Unless otherwise defined herein, suitable heteroaryl groups include pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, thienyl, benzthienyl, imidazolyl, oxadiazolyl and thiadiazolyl groups.
The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine.
Suitable pharmaceutically acceptable salts of the NK-1 receptor antagonists of use in the present invention include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise the quaternary ammonium salts in which the amino nitrogen atom carries an alkyl, alkenyl, alkynyl or aralkyl group. Where the compound carries an acidic group, for example a carboxylic acid group, the present invention also contemplates salts thereof, preferably non-toxic pharmaceutically acceptable salts thereof, such as the sodium, potassium and calcium salts thereof.
WO 00/07598 PCT/GB99/02509 -36- The compounds of use in this invention may have one or more chiral centers and the present compounds may occur as racemates, racemic mixtures and as individual diasteriomers or enantiomers with all such isomeric forms and mixtures thereof being included within the scope of this invention. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water or common organic solvents. Such solvates and hydrates, as well as anhydrous compositions, are encompassed within the scope of this invention. Some of the compounds described herein may contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
Pharmaceutically acceptable salts and derivatives of the bisphosphonates are also useful herein. Nonlimiting examples of salts include those selected from the group consisting alkali metal, alkaline metal, ammonium, and mono-, di, tri-, or tetra-Cl-C3o-alkyl-substituted ammonium. Preferred salts are those selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.
Nonlimiting examples of derivatives include those selected from the group consisting of esters, hydrates, and amides.
It should be noted that the terms "bisphosphonate" and "bisphosphonates", as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates, biphosphonic acids, and diphosphonic acids, as well as salts and derivatives of these materials. The use of a specific nomenclature in referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated. Because of the mixed nomenclature currently in use by those or ordinary skill in the art, reference to a specific weight or percentage of a bisphosphonate compound in the present invention is on an acid active weight basis, WO 00/07598 PCT/GB99/02509 -37unless indicated otherwise herein. For example, the phrase "about 70 mg of a bone resorption inhibiting bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof, on an alendronic acid active weight basis" means that the amount of the bisphosphonate compound selected is calculated based on 70 mg of alendronic acid.
As stated above, the NK-1 receptor antagonist and the bisphosphonate may be formulated in a single pharmaceutical composition or alternatively in individual pharmaceutical compositions for simultaneous, separate or sequential use in accordance with the present invention.
Preferably the compositions according to the present invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, by inhalation or insufflation or administration by transdermal patches or by buccal cavity absorption wafers. Oral dosage forms are particularly preferred tablets, capsules, pills or wafers).
For preparing solid compositions such as tablets, the principal active ingredient can be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like; for oral administration in liquid form, elixirs and syrups, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated. Suitable binders can include starch, gelatin, natural sugars such a glucose, anhydrous lactose, free-flow lactose, beta-lactose, and corn sweeteners, natural and synthetic gums, such as acacia, guar, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like. Lubricants used in WO 00/07598 PCT/GB99/02509 -38these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
A particularly preferred tablet formulation for alendronate monosodium trihydrate is that described in U.S. Patent No. 5,358,941, to Bechard et al, issued October 25, 1994, which is incorporated by reference herein in its entirety. The compounds used in the present method can also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxylpropylmethacrylamide, and the like.
In the preparation of solid oral dosage forms, a solid preformulation composition containing a homogeneous mixture of one or more compounds of the present invention or a non-toxic pharmaceutically acceptable salt thereof, is conveniently prepared. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
WO 00/07598 PCT/GB99/02509 -39- The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, peanut oil or soybean oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
Preferred compositions for administration by injection include those comprising a NK-1 receptor antagonist as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).
Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans TweenTM 20, 40, 60, 80 or and other sorbitans Span
T
20, 40, 60, 80 or 85). Compositions with a surface-active agent will conveniently comprise between 0.05 and surface-active agent, and preferably between 0.1 and It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
Suitable emulsions may be prepared using commercially available fat emulsions, such as IntralipidTM, LiposynTM, InfonutrolTM, LipofundinTM and Lipiphysan
TM
The active ingredient may be either dissolved in a premixed emulsion composition or alternatively it may be dissolved in an oil soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid egg phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example, between 5 and The fat emulsion will preferably comprise fat droplets between 0.1 WO 00/07598 PCT/GB99/02509 and 1.Om, particularly 0.1 and 0.5gum, and have a pH in the range of to Particularly preferred emulsion compositions are those prepared by mixing a NK-1 receptor antagonist selected from the compounds of formulae (III), (VII), (VIII), (XI) and (XII) with IntralipidTM or the components thereof (soybean oil, egg phospholipids, glycerol and water).
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
Compositions of the present invention may also be presented for administration in the form of trans-dermal patches using conventional technology. The compositions may also be administered via the buccal cavity using, for example, absorption wafers.
The present invention further provides a process for the preparation of a pharmaceutical composition comprising a NK-1 receptor antagonist and a bisphosphonate, which process comprises bringing a NK-1 receptor antagonist and a bisphosphonate, into association with a pharmaceutically acceptable carrier or excipient.
When administered in combination, either as a single or as separate pharmaceutical composition(s), the NK-1 receptor antagonist and WO 00/07598 PCT/GB99/02509 -41 bisphosphonate, are presented in a ratio which is consistent with the manifestation of the desired effect. In particular, the ratio by weight of the NK-1 receptor antagonist and the bisphosphonate will suitably be between 0.001 to 1 and 1000 to 1, and especially between 0.01 to 1 and 100 to 1.
A suitable dosage level for the NK-1 receptor antagonist about 0.05 to 1500mg per day, preferably about 0.25 to 1500mg per day, and especially about 0.25 to 500mg per day. Preferred oral dosages in humans may include 10mg, 30mg, 100mg and 300mg of the NK-1 receptor antagonist per dose. The compounds may be administered on a regimen of up to 6 times per day, preferably 1 to 4 times per day, especially 1 or 2 times daily.
A suitable dosage level for the bisphosphonate is between 0.05 mg per kg of body weight per day (mg/kg/day) to about 1.0 mg/kg/day.
Preferred oral dosages in humans may range from daily total dosages of about 2.5-20 mg/day over the effective treatment period, and a preferred prophylactic amount is 2.5, 5, or 10 mg/day.
Alendronate may be administered in a single daily dose or in a divided dose. It is desirable for the dosage to be given in the absence of food, preferably from about 30 minutes to 2 hours prior to a meal, such as breakfast, to permit adequate absorption.
A suitable dosage level for the estrogen or androgen receptor modulator is between about 0.1 and 100 mg/day, and preferably between about 0.1 and 10 mg/day, depending on the potency of the agent.
It will be appreciated that the amount of the NK-1 receptor antagonist and (where present) the additional active agent(s) required for use in the treatment or prevention of abnormal bone resorption will vary not only with the particular compounds or compositions selected but also with the route of administration, the nature of the condition being treated, WO 00/07598 PCT/GB99/02509 -42and the age and condition of the patient, and will ultimately be at the discretion of the patient's physician or pharmacist.
The compounds of formulae (III), (VII), (VIII), (XI) and (XII) may be prepared by the methods described in EP-A-0 577 394 (or WO 95/16679), WO 95/18124, WO 95/23798, WO 97/49710, EP-A-0 436 334, WO 93/21155, EP-A-0 591 040, EP-A-0 532 456, EP-A-0 443 132, WO 92/17449, WO 95/08549 and WO 95/14017, respectively.
Particularly preferred NK-1 receptor antagonists of the formulae (III), (VII), (VIII), (XI) and (XII) for use in the present invention are compounds which are potent NK-1 receptor antagonists, i.e. compounds with an NK-1 receptor affinity (ICoo) of less than 100nM.
Even more preferred NK-1 receptor antagonists of use in the present invention are compounds which are potent NK-1 receptor antagonists with an NK-1 receptor affinity (ICo) of less than favourably less than 2nM and preferably less than InM.
Especially preferred NK-1 receptor antagonists of use in the present invention are orally active, long acting, NK-1 receptor antagonists, identified using a combination of the following assays: ASSAY 1: NK-1 Receptor binding NK-1 receptor binding assays are performed in intact Chinese hamster ovary (CHO) cells expressing the human NK-1 receptor using a modification of the assay conditions described by Cascieri et al, J.
Pharmacol. Exp. Ther., 1992, 42, 458. Typically, the receptor is expressed at a level of 3x10 5 receptors per cell. Cells are grown in monolayer culture, detached from the plate with enzyme-free dissociation solution (Speciality Media Inc.), and washed prior to use in the assay. 1 2 'I-Tyr 8 -substance P nM, 2000Ci/mmol; New England Nuclear) is incubated in the presence or absence of test compounds (dissolved in 51l dimethylsulphoxide, WO 00/07598 PCT/GB99/02509 -43- DMSO) with 5x104 CHO cells. Ligand binding is performed in 0.25ml of Tris-HC1, pH7.5, containing 5mM MnC12, 150mM NaC1, 0.02% bovine serum albumin (Sigma), 50g/ml chymostatin (Peninsula), 0.lnM phenylmethylsulphonyl fluoride, 24g/ml pepstatin, 24g/ml leupeptin and 2.8tg/ml furoyl saccharine. The incubation proceeds at room temperature until equilibrium is achieved (>40 minutes) and the receptor-ligand complex is harvested by filtration over GF/C filters pre-soaked in 0.1% polyethylenimine using a Tomtek 96-well harvester. Non-specific binding is determined using excess substance P (lpM) and represents <10% of total binding.
ASSAY 2: Gerbil Foot-Tapping Long acting NK-1 receptor antagonists for use in the present invention can be identified by their ability to inhibit foot tapping in gerbils induced by central infusion of NK-1 receptor agonists such as GR73632 based on the method of Rupniak Williams, Eur. J. Pharmacol., 1994, 265, 179.
Male or female Mongolian gerbils (35-70g) are anaesthetised by inhalation of an isoflurane/oxygen mixture to permit exposure of the jugular vein in order to permit administration of test compounds or vehicle in an injection volume of approximately 5ml/kg i.v. Alternatively, test compounds may be administered orally or by subcutaneous or intraperitoneal routes. A skin incision is then made in the midline of the scalp to expose the skull. A selective NK-1 receptor agonist GR73632 (d Ala[L-Pro 9 ,Me-Leu] 0 -substance is infused directly into the cerebral ventricles 3pmol in 5i1 depending on test substance) by vertical insertion of a cuffed 27 gauge needle to a depth of 4.5mm below bregma. The scalp incision is closed and the animal allowed to recover from anaesthesia in a clear perspex observation box (approximately x 20cm x 20cm). The duration of hind foot tapping is then recorded continuously for approximately 5 minutes.
WO 00/07598 PCT/GB99/02509 -44- Duration of action may be determined by comparing the effect of the test compound on foot tapping when administered five minutes or 1 hour before NK-1 agonist challenge, against the effect when the test compound is administered 24 hours before the NK-1 agonist challenge.
ASSAY 3: Ferret Emesis Individually housed male ferrets (1.0 -2.5 kg) are dosed orally by gavage with test compound. Ten minutes later they are fed with approximately 100g of tinned cat food. At 60 minutes following oral dosing, cisplatin (10mg/kg) is given i.v. via a jugular vein catheter inserted under a brief period of halothane anaesthesia. The catheter is then removed, the jugular vein ligated and the skin incision closed. The ferrets recover rapidly from the anaesthetic and are mobile within 10-20 minutes. The animals are observed continuously during recovery from the anaesthetic and for 4 hours following the cisplatin injection, after which time the animals are killed humanely. The numbers of retches and vomits occurring during the 4 hours after cisplatin administration are recorded by trained observers.
ASSAY 4: Ovariectomized Rat Long acting NK-1 receptor antagonists for use in the present invention can be identified by their ability to inhibit abnormal bone resorption induced by ovariectomy in six-month old rats, as described in Wronski et al. Endocrinology 123:681-686 (1988). Since estrogen deficiency is the main risk factor for post-menopausal osteoporosis in people, abnormal bone resorption in the OVX rat model is extremely relevant to the human condition.
Ovariectomy (OVX) is completed by dorsal or ventral approach; sham-surgery is completed in age/sex-matched rats. Test compounds are administered orally, subcutaneously, or intraperitoneally to OVX rats WO 00/07598 PCT/GB99/02509 beginning the day after surgery. All rats are killed at four weeks post-surgery.
Bone loss accompanied by accelerated bone resorption and formation in OVX rats is detectable by techniques that are routinely applied in humans. These include measurement of: 1) bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA) in bone regions that contain varying amounts of cortical and trabecular bone (central femur [cortical] and distal femur [trabecular]); 2) urinary deoxypyridiniline crosslinks (uDPD), a biochemical marker of bone turnover; and 3) bone turnover via quantitation of in vivo fluorochrome labelled bone forming surfaces (mineralizing surface; MS/BS) on histologic sections in cancellous bone of the proximal tibia.
BMD significantly above, uDPD significantly below, and MS/BS significantly below that seen in OVX rats after four weeks treatment, are regarded as coordinated signs of test compound efficacy in preventing abnormal bone resorption associated with acute estrogen deficiency.
A typical experimental design using the OVX rat assay in an active pre-clinical development program has six groups: a) Sham-operation b) Ovariectomy (OVX) c) OVX+Low Dose NK-1 Antagonist d) OVX+Medium Dose NK-1 Antagonist e) OVX+High Dose NK-1 Antagonist f) OVX+.OO3mpk daily alendronate Alendronate, a known inhibitor of abnormal bone resorption, and a drug already approved for the prevention/treatment of osteoporosis, is used as a positive control.
A suitable selection cascade for NKi antagonists of use according to the present invention is as follows: WO 00/07598 PCT/GB99/02509 -46- Determine affinity for human NKI receptor in radioligand binding studies (Assay select compounds with IC 5 0 o 10nM, preferably ICno 2nM, especially ICoo 5 InM.
(ii) Determine ability of compounds to inhibit foot tapping in gerbils induced by central injection of an NKi agonist (Assay select compounds that inhibit foot tapping with ID5o 3mg/kg and preferably ID 5 o Img/kg i.v. when administered immediately prior to central NKi agonist challenge, or ID5o 30mg/kg and preferably ID 5 so 10mg/kg p.o. 1 hour prior to challenge.
(iii) Determine duration of action of compounds in gerbil foot tapping assay following intravenous administration 24 hours prior to central NKi agonist challenge; select compounds showing 25-fold loss of potency compared with IDo5 determined in step (ii) above with the proviso that ID 5 o 10mg/kg and preferably 5mg/kg i.v. after 24 hour pre-treatment.
(iv) Determine oral bioavailability of compounds by pharmacokinetic analysis, activity in gerbil foot tapping assay following oral administration and/or by ability to inhibit cisplatin-induced emesis in ferrets (Assay select compounds with IDoo 3mg/kg and preferably IDoo I1mg/kg p.o.
Determine ability of orally-administered compounds to inhibit abnormal bone resorption induced by ovariectomy in adult female rats (Assay select compounds with ID90 (3mg/kg and preferably (Img/kg Particularly preferred compounds of use in the present invention may be selected from those compounds which satisfy the NK- 1 receptor binding criteria of step which, in addition, have 5-fold shift in affinity when incubated in the presence of human serum albumin (HSA) to show non-specific protein binding.
One example of a NK- 1 receptor antagonist of use in the present invention is the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)- WO 00/07598 PCT/GB99/02509 -47ethoxy)-3-(S)-(4-fluorophenyl)-4-( 3 -(5-oxo- 1H,4H- 1,2,4-triazolo)methyl)morpholine, the preparation of which is described in International Patent Specification No. WO 95/16679. In the aforementioned assays, this compound has the following activity: human NK-1 receptor binding: IC 5 o=0. InM gerbil foot-tapping (5 mins.): ID 5 o=0.36mg/kg i.v.
gerbil foot-tapping (24 hrs.): IDso=0.33mg/kg i.v.
ferret emesis: ID9o<3mg/kg p.o.
Another example of a NK-1 receptor antagonist of use in the present invention is the compound 1,2,3triazol-4-yl)methyl-3-(S)-phenylmorpholine, the preparation of which is described in International Patent Specification No. WO 95/18124. In the aforementioned assays, this compound has the following activity: human NK-1 receptor binding: ICo=0.25nM gerbil foot-tapping (5 mins.): IDo=0.12mg/kg i.v.
gerbil foot-tapping (24 hrs.): IDso=0.17mg/kg i.v.
The following examples illustrate pharmaceutical compositions according to the invention.
These formulations may be prepared with separate active ingredients or with a combination of active ingredients in one composition.
In such combined preparations, the ratio of the NK-1 receptor antagonist and the anorectic agent will depend upon the choice of active ingredients.
WO 00/07598 PCT/GB99/02509 -48- EXAMPLE 1 Amount (mg) per tablet NK-1 receptor antagonist 50.0 100.0 300.0 Microcrystalline cellulose 80.0 80.0 80.0 Modified food corn starch 80.0 80.0 80.0 Lactose 189.5 139.5 139.5 Magnesium Stearate 0.5 0.5 The active ingredient, cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 50mg, 100mg and 300mg of the NK-1 receptor antagonist per tablet.
EXAMPLE 2 Bisphosphonate containing tablets are prepared using standard mixing and formation techniques as described in U.S. Patent No.
5,358,941, to Bechard et al., issued October 25, 1994, which is incorporated by reference herein in its entirety.
Tablets containing about 35 mg of alendronate, on an alendronic acid active basis, are prepared using the following relative weights of ingredients.
Ingredient Per Tablet Per 4000 Tablets Alendronate Monosodium Trihydrate 45.68 mg 182.72 g Anhydrous Lactose, NF 71.32 mg 285.28 g Microcrystalline Cellulose, NF 80.0 mg 320.0 g Magnesium Stearate, NF 1.0 mg 4.0 g Croscarmellose Sodium, NF 2.0 mg 8.0 g WO 00/07598 PCT/GB99/02509 49 Tablets comprising other relative weights of alendronate, on an alendronic acid active basis may also be prepared: about 8.75, 17.5, and 140 mg per tablet. Also, tablets containing other bisphosphonates at appropriate active levels are similarly prepared: cimadronate, clodronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, and pharmaceutically acceptable salts thereof.
Also, tablets containing combinations of bisphosphonates are similarly prepared.
EXAMPLE 3 Amount (mg) per tablet NK-1 Receptor Antagonist 50.0 100.0 300.0 Alendronate Monosodium 45.0 45.0 45.0 Trihydrate Microcrystalline Cellulose 80.0 80.0 80.0 Modified Food Corn Starch 80.0 80.0 80.0 Lactose 144.5 194.5 144.5 Magnesium Stearate 0.5 0.5 The active ingredients cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 50mg, 100mg and 300mg of the NK-1 receptor antagonist and 45mg of alendronate monosodium trihydrate per tablet.
Claims (21)
1. Use of a NK-1 receptor antagonist of formula 3 4 R N R X R 1 1 R or a pharmaceutically acceptable salt thereof, wherein: R 1 is selected from the group consisting of: C1-6alkyl, substituted with one or more of the substituents selected from: heterocycle, wherein the heterocycle is selected from the group consisting of: benzimidazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrrolyl, tetrazolyl, thiadiazolyl, triazolyl, and piperidinyl, and wherein the heterocycle is unsubstituted or substituted with one or more substituent(s) selected from: Cl-6alkyl, unsubstituted or substituted with halo, -CF 3 -OCH 3 or phenyl, WO 00/07598 PCT/GB99/02509 51 (ii) C1. 6 alkoxy, (iii) oxo, (iv) thioxo, cyano, (vi) -SCH 3 (vii) phenyl, (viii) hydroxy, (ix) trifluoromethyl, (x -(CH2)m-NR 9 R 1 0 wherein mi is 0, 1 or 2, and R 9 and R' 0 areindependently selected from: hydrogen, (II) CI-6alkyl, (III) hydroxyCl.6alkyl, and (IV) phenyl, (xi) NR9CORI 0 wherein R 9 and RIO are as defined above, and (xii) -CONR 9 R 1 0 wherein R 9 and R' 0 are as defined above, R 2 and R 3 are independently selected from the group consisting of: hydrogen; Ci- 6 alkyl C 2 -6alkenyl, and phenyl; X is R 4 1s R 5 is phenyl, unsubstituted or substituted with halo;, R 6 R1 and R 8 are independently selected from the group consisting of: hydrogen, WO 00/07598 PCT/GB99/02509 52 C1.6alkyl, halo, and -CF 3 Y is and Z is hydrogen or Ci4alkyl; or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption.
2. Use as claimed in Claim 1 wherein said compound of formula is selected from: 1,2,4-triazolo)methyl)-2(S)-(3 ,5-bis(trifluoromethyl)benzyloxy)-3(S)- phenyl-morpholine; 1,2 ,4-triazolo)methyl)-2(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(R)- phenyl-morpholine;
4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-2(S bis(trifluoromethyl)benzyloxy)-3(S)-phenyl-morpholine; and ,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)- 4-(3-(5-oxo- 1H,4H- 1,2,4-triazolo)methyl)morpholine; or a pharmaceutically acceptable salt thereof. 3. Use of a NK-1 receptor antagonist of formula (II): A 1 0 0" 2 WO 00/07598 PCT/GB99/02509 -53- wherein: A 1 is fluorine or CF3; A 2 is fluorine or CF 3 A 3 is fluorine or hydrogen; R 6 is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =S or a C1-4alkyl group, and optionally substituted by a group of the formula ZNR 7 R 8 where Z is C.-6alkylene or C3-6cycloalkylene; R 7 is hydrogen, C1-4alkyl, Cs.7cycloalkyl or C3.7cycloalkylC1- 4 alkyl, or C24alkyl substituted by C1-4alkoxy or hydroxyl; R 8 is hydrogen, C1.4alkyl, C3s7cycloalkyl or C3-7cycloalkylC1-4alkyl, or C2-4alkyl substituted by one or two substituents selected from CI-4alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S; or R 7 R 8 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by a hydroxy group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(0) or S(0)2 or a second nitrogen atom which will be part of a NH or NRC moiety where RC is C1.4alkyl optionally substituted by hydroxy or C1-4alkoxy; or R 7 R 8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms; or Z, R 7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo; and Y is a C1- 4 alkyl group optionally substituted by a hydroxyl group; with the proviso that ifY is C1. 4 alkyl, R 6 is susbstituted at least by a group of formula ZNR 7 R 8 as defined above; or a pharmaceutically acceptable salt thereof; 54 for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption. 4. Use as claimed in Claim 3 wherein said compound of formula (11) is selected from: ,-bis(trifluoromethyl)pheny1 )ethoxy)-4-(5-(dimethylamjfl 0 methyl-l,2,3-triazol.4.yl)methy13(S)-phenylmorphoVn methyl-i ,-rao--lmehl3()(-lorpey~opoie ,S-bis(trifluoromethyl)phenyl)2hydroetho) 3 4 fluorophenyl l, 2 4 -triazol-3-yl)methylmorpholine; or a pharmaceutically acceptable salt thereof. Use of a NK-1 receptor antagonist of formula (111):. R 3 0 yR7 8 z R (III) (O)p 13~ R1 wherein: R2 and R3 are independently selected from the group consisting of: hydrogen, C1..6alkyl, (3 C2..6alkenyl, and phenyl; R6, R 7 and R8 are independently selected from the group consisting of: hydrogen, 23 Ci-6alkyl, fluoro, WO 00/07598 PCT/GB99/02509 55 chioro, bromo, iodo, and -CF 3 R 12 and R1 3 are independently selected from the group consisting of: fluoro, chioro, bromo, and iodo; A is unsubstituted l.6alkyl; B is selected from the group consisting of: HH vNo. N-N N0 IN 0N 0 X H x H N-N 4x -S N- x x N-N N x N- H H N-N N 0, x N-N N N x N x x N 0 H N x H 1 N N 0 x N H H N p isO0 or 1; WO 00/07598 PCT/GB99/02509 56 X is selected from: -PO(OH)O- wherein M' is a pharmaceutically acceptable monovalent counterion, -PO(0-) 2 *2MI, -PO(0-) 2 *D 2 wherein D 2 is a pharmaceutically acceptable divalent counterion, -CH(R4)-PO(OH)O- wherein R 4 is hydrogen or CI- 3 alkyl, -CH(R4)-PO(O-) 2 2MI, -CH(R4)-PO(O-) 2 2* -CO-CH 2 CH 2 -C0 2 M -CH(CH 3 )-O-CO-R5, wherein R 5 is selected from the group consisting of: 57 (iii)0 0'M OV) CO 2 M 0 CO;M+ 2- CO 2 -Y NH 3 CO,- M+ (Vi) 0 CO, M+ Co., M+ CO~; M+ (vii) and Y is :Z is hydrogen or C1-Galkyl; or a Pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption. 58
6. Use as claimed in Claim 5 wherein said compound of formula (III) is selected from: 5-bis(trifluoromethyl)belZyloxy)- 3 -(S)-phenyl-4-(3-(5-oxo- 1H, 4H-1 4-triazolo)methyl)morpholifle N-oxide; 5-bis(trifluoromethyl)belzyloxy)-3-(S)-phenl-l 4 (ethoxycarbonyloxy- 1-ethyl)-5-oxo- 1H- 1,2,4- triazolo)methyl)morpholifle; fluorophenyl)-4- (3-(4-monophosphoryl- 5-oxo- lH-1,2,4- triazolo)methyl)morpholine; 5.bis(trfuoromethyl)phenyl)ethoxy)-3-(S)-(4---- fluorophenyl)4-(3-(-monophosphoryl 5-oxo-lH- 1,2,4- triazolo)methyl)morpholine; 5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4- fluorophenyl)4-(3-(2-monophosphoryl-5-oxo- 1H- 1,2,4- tr,.azolo)methyl)morpholine; 5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)- (4- fluorophenyl)-4- (3-(5.oxyp hosphoryl- 1H- 1,2,4- triazolo)methyl)morpholine; 5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4- fluorophe-nyl)-4- (3-(1-monophosphoryl-5-oxo-4H- 1,2,4- triazolo)methyl)morpholine; :or a pharmaceutically acceptable salt thereof.
7. Use of a NK-1 receptor antagonist as defined in any one of Claims I. to 6 in combination with one or more active agents selected from V, the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, for the manufacture of a mjedicament for the treatment or prevention of abnormal bone resorption. 59 S. Use as claimed in Claim 7 wherein said bisphosphonate is a compound of formula (XIII): P0 3 H1 2 P0 3 H 2 (XIII) wherein A and X are independently selected from the group consisting of H, OH, halogen, Nz, SH, phenyl, C 1 -Cao alkyl, C.I-C30 cycloalkyl, C 1 -C 3 o substituted alkyl, C 3 -C30 substituted cycloalkyl, Ci-Cio alkyl or C 3 -Clo cycloalkyl. mono- or di- substituted NH 2 CI-Cio alkoxy, Cl-Oj.o alkyl or C3-Clo cycloalkyl. substituted thio, phenyl. substituted thio, Ci-Ojo alkyl or C3-ClO cycloalkyl substituted phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, and benzyl- Use as claimed in Claim 8 wherein said bisphosphonate is selected from the group consisting of alendronate, cimadronate, clodronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, pharmaceutically acceptable salts thereof, and mixtures thereof. Use as claimed in Claim 9 wherein said bisphosphonate is alendronate monosodium trihydrate. 25
11. Use as claimed in Claim 7 wherein said estrogen receptor modulator is selected from the group consisting of estrogen, progestins, .0 00. 60 estradiol, raloxifene, tamoxifene, clometherofle, delinadinofle, droloxifene, idoxifene, nafoxidine, nitromifene, ormeloxifene, toremifene, trioxifene, 327, CP-336 166 and ([-4hdoyhnl-6h~xnphhln1 yl] 2 -(l-piperidil)ethoxy]phefl]l)metharie and their pharmaceutically acceptable salts, and mixtures thereof.
12. Use as claimed in Claim 7 wherein said androgen receptor modulator is selected from the group consisting of danazol, testosterone, nandrolane decanoate, methyltestosterofle, methanadrostelolofle, stanozolol, fluoxymesterofle, oxymetholone, oxandrolone, oxymethol, norethandrolofle, ethylestranol, 4-androsten-1 9 -al- 3
17-dione,
19-nortestosterofle, norethandrone, norethisterone, dehydroepiandrosteronle, epiandrosterofle sulfate, androstenediofle and androstenediol, te stosterone propionate, testosterone cytpionate, and testosterone enanthate- 13. Use a6 claimed in Claim 7 wherein said peptide hormone is calcitonin. 14. Use of a NK-1 receptor antagonist as defined in any one of Claims 1 to 6 and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, for the manufacture of a medicament for the treatment or prevention of abnormal bone resorption. A pharmaceutical composition comprising a NK-1 receptor antagonist as defined in any one of Claims 1 to 6 and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, together with at 30 least one pharmaceutically acceptable carrier or excipient. 61 16. A product comprising a NK-1 receptor antagonist as defined in any one of Claims 1 to 6 and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of abnormal bone resorption. 17. The product as claimed in Claim 16 wherein the condition associated with abnormal bone resorption is selected from the group consisting of generalized bone loss, localized bone loss, and the creation of bone having an abnormal structure. 18. The product as claimed in Claim 17 wherein the condition associated with abnormal bone resorption is selected from the group consisting of the following conditions or disease states: osteoporosis, post-menopausal osteoporosis, glucocorticoid- induced osteoporosis, male osteoporosis, disease-induced osteoporosis, idiopathic osteoporosis, Paget's disease, abnormally increased bone turnover, hypercalcemia of malignancy, osteogensis imperfecta, periodontal disease, periprosthetic osteolysis, and abnormal bone resorption associated with immunosuppressive therapy. 19. A method for the treatment or prevention of abnormal bone resorption said method comprising administration to a patient in need of such treatment a therapeutically effective amount of a NK-1 receptor antagonist of formula as defined in claim 1. A method for the treatment or prevention of abnormal bone resorption said method comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of formula (II) as defined in claim 3.
21. A method for the treatment or prevention of abnormal bone resorption said method comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of formula (III), as defined in claim
22. A method for the treatment or prevention of abnormal bone resorption said method comprising administration to a patient in need of such treatment a therapeutically effective amount of a NK-1 receptor antagonist, as defined in any one of claims 1 to 6 in combination with one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones.
23. A method for the treatment or prevention of abnormal bone resorption said method comprising administration to a patient in need of such treatment a therapeutically effective amount of a NK-1 receptor antagonist, as defined in any one of claims 1 to 6 and one or more active agents selected from the group consisting of bisphosphonates, estrogen S" and androgen receptor modulators, and peptide hormones. [I:\DAYLIB\LIBH]02553.doc:sxc 62
24. A NK-1 receptor antagonist of formula as defined in claim 1, when used for the treatment or prevention of abnormal bone resorption. A NK-1 receptor antagonist of formula (II) as defined in claim 3, when used for the treatment or prevention of abnormal bone resorption.
26. A NK-1 receptor antagonist of formula (III) as defined in claim 5 when used for the treatment or prevention of abnormal bone resorption.
27. A NK-1 receptor antagonist, as defined in any one of claims 1 to 6 in combination with one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, o0 when used for the treatment or prevention of abnormal bone resorption.
28. A NK-1 receptor antagonist, as defined in any one of claims 1 to 6 and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, when used for the treatment or prevention of abnormal bone resorption.
29. The use of any one of claims 1 to 14 or 24 to 28 wherein the condition associated with abnormal bone resorption is selected from the group consisting of generalized bone loss, localized bone loss, and the creation of bone having an abnormal structure. The use as claimed in claim 29 wherein the condition associated with abnormal bone resorption is selected from the group consisting of the following conditions or disease states: osteoporosis, post-menopausal osteoporosis, glucocorticoid- induced osteoporosis, male osteoporosis, disease-induced osteoporosis, idiopathic osteoporosis, Paget's disease, abnormally increased bone turnover, hypercalcemia of malignancy, osteogensis imperfecta, periodontal disease, periprosthetic osteolysis, and abnormal bone resorption associated with immunosuppressive therapy.
31. The method of any one of claims 19 to 23 wherein the condition associated with abnormal bone resorption is selected from the group consisting of generalized bone loss, localized bone loss, and the creation of bone having an abnormal structure.
32. The method of claim 31 wherein the condition associated with abnormal bone resorption is selected from the group consisting of the following conditions or disease states: osteoporosis, post-menopausal osteoporosis, glucocorticoid-induced osteoporosis, male osteoporosis, disease-induced osteoporosis, idiopathic osteoporosis, Paget's disease, abnormally increased bone turnover, hypercalcemia of malignancy, osteogensis imperfecta, periodontal disease, periprosthetic osteolysis, and abnormal bone resorption 35 associated with immunosuppressive therapy. S. [I:\DAYL1B\LBH02553.doc:sxc 63
33. A pharmaceutical composition comprising a NK-1 receptor antagonist as defined in any one of Claims 1 to 6 and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, together with at least one pharmaceutically acceptable carrier or excipient substantially as hereinbefore described with reference to Example 3.
34. A process for preparing a pharmaceutical composition comprising a NK-1 receptor antagonist as defined in any one of Claims 1 to 6 and one or more active agents selected from the group consisting of bisphosphonates, estrogen and androgen receptor modulators, and peptide hormones, together with at least one pharmaceutically acceptable carrier or excipient substantially as hereinbefore described with reference to Example 3. A pharmaceutical composition when prepared by the process of claim 34. Dated 22 May, 2003 Merck Sharp Dohme Limited Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [I:\DAYIB\LIBH]02553.doc:sxc S. [I:\DAYLIB\LIBH]02553.doc:sxc
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9816897.4A GB9816897D0 (en) | 1998-08-04 | 1998-08-04 | Therapeutic use |
GB9816897 | 1998-08-04 | ||
PCT/GB1999/002509 WO2000007598A1 (en) | 1998-08-04 | 1999-07-30 | Use of a nk-1 receptor antagonist for treating or preventing abnormal bone resorption |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5059999A AU5059999A (en) | 2000-02-28 |
AU763615B2 true AU763615B2 (en) | 2003-07-31 |
Family
ID=10836638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU50599/99A Ceased AU763615B2 (en) | 1998-08-04 | 1999-07-30 | Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1102590A1 (en) |
JP (1) | JP2002522389A (en) |
AU (1) | AU763615B2 (en) |
CA (1) | CA2339146A1 (en) |
GB (1) | GB9816897D0 (en) |
WO (1) | WO2000007598A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK622004A3 (en) | 2001-07-31 | 2004-08-03 | Pfizer Prod Inc | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
CN107868117B (en) * | 2016-09-28 | 2021-04-23 | 中国科学院苏州纳米技术与纳米仿生研究所 | Stenazole saccharinate and preparation method and application thereof |
CN109694390A (en) * | 2017-10-24 | 2019-04-30 | 齐鲁制药有限公司 | A kind of Fosaprepitant nitrogen oxides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018124A1 (en) * | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
WO1995023798A1 (en) * | 1994-03-04 | 1995-09-08 | Merck & Co., Inc. | Prodrugs of morpholine tachykinin receptor antagonists |
WO1998043639A1 (en) * | 1997-04-03 | 1998-10-08 | Eli Lilly And Company | Methods of treating bone loss |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8929070D0 (en) * | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
CA2106200C (en) * | 1991-03-26 | 1996-11-19 | Terry J. Rosen | Stereoselective preparation of substituted piperidines |
MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
FR2689888B1 (en) * | 1992-04-10 | 1994-06-10 | Rhone Poulenc Rorer Sa | NOVEL PERHYDROISOINDOLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
FR2696178B1 (en) * | 1992-09-30 | 1994-12-30 | Sanofi Elf | Quaternary basic amides, process for their preparation and pharmaceutical compositions containing them. |
FR2700472B1 (en) * | 1993-01-19 | 1995-02-17 | Rhone Poulenc Rorer Sa | Synergizing association having an antagonistic effect on the NK1 and NK2 receptors. |
FR2703679B1 (en) * | 1993-04-05 | 1995-06-23 | Rhone Poulenc Rorer Sa | NOVEL PERHYDROISOINDOLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
IL111002A (en) * | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | Piperidine derivatives their preparation and pharmaceutical compositions containing them |
US6403577B1 (en) * | 1993-11-17 | 2002-06-11 | Eli Lilly And Company | Hexamethyleneiminyl tachykinin receptor antagonists |
RU2151769C1 (en) * | 1994-07-12 | 2000-06-27 | Эли Лилли Энд Компани | (r)-3-(1h-indole-3-yl)-1-[n-(2-methoxybenzyl)acetylamino]-2- -[n-(2-(4-piperidine-1-yl)piperidine-1-yl)acetyl)amino]propane dihydrochloride trihydrate and pharmaceutical composition |
WO1996037207A2 (en) * | 1995-05-25 | 1996-11-28 | Biofrontiers, Inc. | Pharmaceutical compositions containing calcium sulfate |
WO1997007117A1 (en) * | 1995-08-21 | 1997-02-27 | Eli Lilly And Company | 2-acylaminopropanamines as growth hormone secretagogues |
EP0906315A1 (en) * | 1996-06-21 | 1999-04-07 | MERCK SHARP & DOHME LTD. | Spiro-piperidine derivatives and their use as therapeutic agents |
-
1998
- 1998-08-04 GB GBGB9816897.4A patent/GB9816897D0/en not_active Ceased
-
1999
- 1999-07-30 EP EP99934993A patent/EP1102590A1/en not_active Withdrawn
- 1999-07-30 JP JP2000563283A patent/JP2002522389A/en not_active Withdrawn
- 1999-07-30 CA CA002339146A patent/CA2339146A1/en not_active Abandoned
- 1999-07-30 WO PCT/GB1999/002509 patent/WO2000007598A1/en not_active Application Discontinuation
- 1999-07-30 AU AU50599/99A patent/AU763615B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018124A1 (en) * | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
WO1995023798A1 (en) * | 1994-03-04 | 1995-09-08 | Merck & Co., Inc. | Prodrugs of morpholine tachykinin receptor antagonists |
WO1998043639A1 (en) * | 1997-04-03 | 1998-10-08 | Eli Lilly And Company | Methods of treating bone loss |
Also Published As
Publication number | Publication date |
---|---|
WO2000007598A1 (en) | 2000-02-17 |
JP2002522389A (en) | 2002-07-23 |
EP1102590A1 (en) | 2001-05-30 |
CA2339146A1 (en) | 2000-02-17 |
GB9816897D0 (en) | 1998-09-30 |
AU5059999A (en) | 2000-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU735760B2 (en) | Use of a NK-1 receptor antagonist and an SSRI for treating obesity | |
EP1299093A2 (en) | Combinations of bisphosphonates, estrogenic agents and optionally estrogens | |
JP2009137970A (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitor | |
ZA200301004B (en) | Pharmaceutical compositions of estrogenic agents. | |
WO2002003992A2 (en) | Use of substituted indole compounds for treating prosthesis-related bone degeneration | |
EP1311293A2 (en) | Combinations of ssri and estrogenic agents | |
US20040259850A1 (en) | Method for treating or preventing symptoms of hormonal variation including hot flashes | |
WO2002004418A2 (en) | Methods of inhibiting uterotrophic effects of estrogenic agents | |
WO2002003977A2 (en) | Combinations of statins, estrogenic agents and optionally estrogens | |
CA2414111A1 (en) | Use of substituted indole compounds for increasing nitric oxide synthase activity | |
WO1999059583A1 (en) | Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia | |
US20080161307A1 (en) | Organic Compounds | |
AU763615B2 (en) | Use of a NK-1 receptor antagonist for treating or preventing abnormal bone resorption | |
EP1233766A1 (en) | Use of synergistic combinations of a nk 1? receptor antagonist and a gaba analog in psychiatric disorders | |
JP2000505808A (en) | Method for inhibiting Elf5A biosynthesis | |
AU744261B2 (en) | Use of NK-1 receptor antagonists for treating eating disorders | |
AU749976B2 (en) | Method for treating premenstrual or late luteal phase syndrome | |
US20020028792A1 (en) | Combinations of bisphosphonates, estrogens and estrogenic agents | |
WO1999059635A1 (en) | Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation | |
US20020019373A1 (en) | Combinations of bisphosphonates and estrogenic agents | |
US20020025952A1 (en) | Combinations of statins, estrogens and estrogenic agents | |
AU738047B2 (en) | Use of NK-1 receptor antagonists for treating mania | |
US20020142942A1 (en) | Method for treating premenstrual or late luteal phase syndrome | |
WO1999027938A1 (en) | Method for treating or preventing psychosomatic and psychoimmunologic disorders | |
CA2324116A1 (en) | Nk-1 receptor antagonists and eletriptan for the treatment of migraine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |